

TOPCO SCIENTIFIC CO., LTD.**Financial Statements****With Independent Auditors' Report
For the Years Ended December 31, 2025 and 2024**

Address: 6F., No. 176, Zhouzi Street, Neihu District, Taipei City
Telephone: 02-87978020

The independent auditors' report and the accompanying financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' report and financial statements, the Chinese version shall prevail.

Table of contents

Contents	Page
1. Cover Page	1
2. Table of Contents	2
3. Independent Auditors' Report	3
4. Balance Sheets	4
5. Statements of Comprehensive Income	5
6. Statements of Changes in Equity	6
7. Statements of Cash Flows	7
8. Notes to the Financial Statements	
(1) Company history	8
(2) Approval date and procedures of the financial statements	8
(3) New standards, amendments and interpretations adopted	8~10
(4) Summary of material policies	10~26
(5) Significant accounting assumptions and judgments, and major sources of estimation uncertainty	26
(6) Explanation of significant accounts	26~61
(7) Related-party transactions	62~66
(8) Pledged assets	66
(9) Commitments and contingencies	66~67
(10) Losses Due to Major Disasters	67
(11) Subsequent Events	67
(12) Other	67~68
(13) Other disclosures	
(a) Information on significant transactions	68, 69~71
(b) Information on investees	68, 72~73
(c) Information on investment in mainland China	68, 74
(14) Segment information	68
9. List of major account titles	75~81



安侯建業聯合會計師事務所

KPMG

台北市110615信義路5段7號68樓(台北101大樓)
68F., TAIPEI 101 TOWER, No. 7, Sec. 5,
Xinyi Road, Taipei City 110615, Taiwan (R.O.C.)

電話 Tel + 886 2 8101 6666
傳真 Fax + 886 2 8101 6667
網址 Web kpmg.com/tw

Independent Auditors' Report

To the Board of Directors of Topco Scientific Co., Ltd.:

Opinion

We have audited the financial statements of Topco Scientific Co., Ltd. (“the Company”), which comprise the balance sheet as of December 31, 2025 and 2024, the statement of comprehensive income, changes in equity and cash flows for the years then ended, and notes to the financial statements, including a summary of material accounting policies.

In our opinion, based on our audits and the reports of other auditors (please refer to Other Matter paragraph), the accompanying financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and its financial performance and its cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers.

Basis for Opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with The Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis of our opinion.

Other Matter

We did not audit the financial statements for certain investments accounted for using equity method in the financial statements of the Company for 2025 and 2024. The investments accounted for using equity method constituted 8.31% and 9.68% of the total assets as of December 31, 2025 and 2024; and the share of profit of associates and joint ventures accounted for using equity method constituted 10.14% and 14.46% of profit before tax for the years ended December 31, 2025 and 2024, respectively. These financial statements were audited by other auditors whose reports have been furnished to us, and our opinion, insofar as it relates to the amount of investments accounted for equity method, is based solely on the reports of the other auditors.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audits of the financial statements of the current period. These matters were addressed in the context of our audits of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matters described below to be the key audit matters to be communicated in our report.

1. Recognition of Operating Revenue

Please refer to note 4(o) "Revenue" for accounting policies related to revenue recognition; and note 6(s) "Revenue" for details of revenue.

Description of Key Audit Matters:

Due to the wide variety of the Company's products, different transactions were generated according to customers and product portfolio. Identification of revenue recognition has significant influence on the financial statements of the Company. Therefore, revenue recognition is considered as one of the key matters in our audits.

How the matter was addressed in our audits:

Our principal audit procedures included: testing related manual and systematic control over sales cycle to assess if the revenue recognition policies of the Company are in accordance with the related standards. In addition, we examined the sales contracts between the Company and its customers to understand their trading modality and conditions, evaluating and comparing if revenue recognition is consistent with the terms of the contracts; conducting testing for details of revenue before and after the balance sheet date and verifying if revenue recognition is in accordance with the contract terms.

2. Investments accounted for using equity method- Recognition of Operating Revenue of subsidiaries

Please refer to note 4(i) "Investment in subsidiary" for accounting policies related to revenue recognition; and note 6(f) Investments accounted for using equity method.

Description of Key Audit Matters:

Some of the Company's subsidiaries, which are recognized under the equity method, are distributors for the purchase and sale of semiconductor material, electronic material and construction of environmental engineering business, such as water purification plants and dust-proof rooms. The amounts and changes in operating revenues, which are significant sources of revenues from the perspective of consolidation, may affect the users' understanding of the overall financial statements. Therefore, we have included this as one of the key audit matters.

How the matter was addressed in our audits:

Our principal audit procedures included: testing related manual and systematic control over sales cycle of certain subsidiaries using the equity method of investment, performing analytical procedures to operating income, and testing relevant vouchers, as well as assessing whether the Company's timing on revenue recognition and the amounts recognized are in accordance with related standards, and acquiring construction contracts that have significant effects on financial results to verify that there is no diffidence in the percentage of completion calculated by the Company.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Regulations Governing the Preparation of Financial Reports by Securities Issuers, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance (including the audit committee) are responsible for overseeing the Company's financial reporting process.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

6. Obtain sufficient and appropriate audit evidence regarding the financial information of the investment in other entities accounted for using the equity method to express an opinion on these financial statements. We are responsible for the direction, supervision and performance of the audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partners on the audit resulting in this independent auditors' report are Kuan-Ying Kuo and Keng-Chia Huang.

KPMG

Taipei, Taiwan (Republic of China)
March 10, 2026

Notes to Readers

The accompanying financial statements are intended only to present the statement of financial position, financial performance and cash flows in accordance with the accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to audit such financial statements are those generally accepted and applied in the Republic of China.

The independent auditors' report and the accompanying financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' report and financial statements, the Chinese version shall prevail.

(English Translation of Financial Statements and Report Originally Issued in Chinese)
TOPCO SCIENTIFIC CO., LTD.

Balance Sheets

December 31, 2025 and 2024

(Expressed in Thousands of New Taiwan Dollars)

Assets		December 31, 2025		December 31, 2024		Liabilities and Equity		December 31, 2025		December 31, 2024	
		Amount	%	Amount	%			Amount	%	Amount	%
Current assets:						Current liabilities:					
1100	Cash and cash equivalents (note 6(a))	\$ 1,354,047	4	656,951	2	2100	Short-term borrowings (note 6(k))	\$ -	-	460,000	2
1110	Current financial assets at fair value through profit or loss (note 6(b))	27	-	-	-	2130	Current contract liabilities (note 6(s))	295,551	1	240,555	1
1170	Notes and accounts receivable, net (note 6(d))	6,102,466	19	4,054,037	15	2170	Notes and accounts payable	6,246,867	20	4,099,358	15
1180	Notes and accounts receivable due from related parties, net (notes 6(d) and 7)	181,884	1	172,705	1	2180	Notes and accounts payable to related parties (note 7)	275,004	1	161,415	1
1476	Other current financial assets (notes 6(j), 7 and 8)	44,101	-	12,530	-	2200	Accrued expenses and other payables	1,231,352	4	998,872	4
1311	Inventories, net (note 6(e))	2,795,003	9	2,246,033	8	2230	Current tax liabilities	404,778	1	293,367	1
1479	Other current assets, others	207,447	1	175,165	1	2280	Current lease liabilities (note 6(n))	39,698	-	37,552	-
		<u>10,684,975</u>	<u>34</u>	<u>7,317,421</u>	<u>27</u>	2321	Bonds payable, current portion (note 6(m))	298,078	1	-	-
						2399	Other current liabilities	74,660	-	79,288	-
Non-current assets:								<u>8,865,988</u>	<u>28</u>	<u>6,370,407</u>	<u>24</u>
1510	Non-current financial assets at fair value through profit or loss (note 6(b))	829,664	3	490,635	2	Non-Current liabilities:					
1517	Non-current financial assets at fair value through other comprehensive income (note 6(c))	1,606,165	5	1,485,750	6	2530	Bonds payable (note 6(m))	-	-	532,746	2
1550	Investments accounted for using equity method (notes 6(f), 6(g) and 7)	10,229,774	32	9,814,133	36	2541	Long-term borrowings (notes 6(l) and 8)	1,900,000	6	1,580,000	6
1600	Property, plant and equipment (notes 6(h) and 8)	7,956,310	25	7,652,034	28	2570	Deferred tax liabilities and others (note 6(p))	664,831	3	678,346	2
1755	Right-of-use assets (note 6(i))	106,650	-	86,410	-	2580	Non-current lease liabilities (note 6(n))	67,060	-	50,783	-
1840	Deferred tax assets (note 6(p))	45,681	-	40,433	-	2640	Non-current net defined benefit liabilities (note 6(o))	139,121	-	137,779	1
1900	Other non-current assets (notes 6(j) and 8)	177,534	1	234,467	1			<u>2,771,012</u>	<u>9</u>	<u>2,979,654</u>	<u>11</u>
		<u>20,951,778</u>	<u>66</u>	<u>19,803,862</u>	<u>73</u>		Total liabilities	<u>11,637,000</u>	<u>37</u>	<u>9,350,061</u>	<u>35</u>
						Equity attributable to owners of parent: (note 6(q))					
						3100	Ordinary shares	1,923,546	6	1,910,393	7
						3200	Capital surplus	3,145,115	10	2,916,241	11
						3300	Retained earnings	13,645,742	43	11,760,485	43
						3400	Other equity	1,285,350	4	1,184,103	4
							Total equity	<u>19,999,753</u>	<u>63</u>	<u>17,771,222</u>	<u>65</u>
Total assets		<u>\$ 31,636,753</u>	<u>100</u>	<u>27,121,283</u>	<u>100</u>	Total liabilities and equity		<u>\$ 31,636,753</u>	<u>100</u>	<u>27,121,283</u>	<u>100</u>

See accompanying notes to financial statements.

(English Translation of Financial Statements and Report Originally Issued in Chinese)
TOPCO SCIENTIFIC CO., LTD.

Statements of Comprehensive Income

For the years ended December 31, 2025 and 2024

**(Expressed in Thousands of New Taiwan Dollars, Except for Earnings
Per Common Share which is expressed in New Taiwan Dollars)**

		<u>2025</u>		<u>2024</u>	
		<u>Amount</u>	<u>%</u>	<u>Amount</u>	<u>%</u>
Operating Revenues: (notes 6(s) and 7)					
4110	Sales revenue	\$ 39,653,996	97	30,146,312	96
4800	Other operating revenue	<u>1,159,791</u>	<u>3</u>	<u>1,108,989</u>	<u>4</u>
	Operating revenue, net	<u>40,813,787</u>	<u>100</u>	<u>31,255,301</u>	<u>100</u>
Operating costs: (notes 6(e), 7 and 12)					
5110	Cost of sales	35,642,614	87	26,953,037	86
5800	Other operating costs	<u>273,929</u>	<u>1</u>	<u>261,189</u>	<u>1</u>
		<u>35,916,543</u>	<u>88</u>	<u>27,214,226</u>	<u>87</u>
	Gross profit	<u>4,897,244</u>	<u>12</u>	<u>4,041,075</u>	<u>13</u>
Operating expenses: (notes 7 and 12)					
6100	Selling expenses	828,938	2	751,673	3
6200	Administrative expenses	1,592,601	4	1,355,355	4
6300	Research and development expenses	<u>26,324</u>	<u>-</u>	<u>37,781</u>	<u>-</u>
	Total operating expenses	<u>2,447,863</u>	<u>6</u>	<u>2,144,809</u>	<u>7</u>
	Net operating income	<u>2,449,381</u>	<u>6</u>	<u>1,896,266</u>	<u>6</u>
Non-operating income and expenses:					
7100	Interest income	12,649	-	10,583	-
7101	Other income (notes 6(b), 6(c) and 6(u))	127,372	-	118,529	-
7102	Other gains and losses (notes 6(b) and 6(u))	385,202	1	105,347	-
7105	Financial costs (note 6(n))	(47,417)	-	(66,625)	-
7060	Share of profits of subsidiaries, associates and joint ventures accounted for using equity method (note 6(f))	<u>2,026,973</u>	<u>5</u>	<u>2,175,924</u>	<u>7</u>
		<u>2,504,779</u>	<u>6</u>	<u>2,343,758</u>	<u>7</u>
7900	Profit from continuing operations before tax	4,954,160	12	4,240,024	13
7950	Less: Income tax expenses (note 6(p))	<u>773,713</u>	<u>2</u>	<u>584,089</u>	<u>2</u>
	Profit	<u>4,180,447</u>	<u>10</u>	<u>3,655,935</u>	<u>11</u>
8300	Other comprehensive income:				
8310	Items that will not be reclassified to profit or loss				
8311	Gains (losses) on remeasurements of defined benefit plans	(2,299)	-	(4,681)	-
8316	Unrealized gains (losses) from investments in equity instruments measured at fair value through other comprehensive income	120,415	-	338,188	1
8330	Share of other comprehensive income of subsidiaries, associates and joint ventures accounted for using equity method, items that will not be reclassified to profit or loss	8,800	-	(18,057)	-
8349	Less: Income tax related to items that will not be reclassified to profit or loss	<u>(460)</u>	<u>-</u>	<u>(936)</u>	<u>-</u>
		<u>127,376</u>	<u>-</u>	<u>316,386</u>	<u>1</u>
8360	Items that will be reclassified to profit or loss				
8361	Exchange differences on translation of foreign financial statements	(34,960)	-	171,376	1
8399	Less: Income tax related to items that will be reclassified to profit or loss	<u>(6,992)</u>	<u>-</u>	<u>34,041</u>	<u>-</u>
	Items that will be reclassified to profit or loss	<u>(27,968)</u>	<u>-</u>	<u>137,335</u>	<u>1</u>
8300	Other comprehensive income	<u>99,408</u>	<u>-</u>	<u>453,721</u>	<u>2</u>
	Comprehensive income	<u>\$ 4,279,855</u>	<u>10</u>	<u>4,109,656</u>	<u>13</u>
	Earnings per share: (note 6(r))				
9750	Basic earnings per share (NT Dollars)	<u>\$ 21.81</u>		<u>19.29</u>	
9850	Diluted earnings per share (NT Dollars)	<u>\$ 21.40</u>		<u>18.78</u>	

See accompanying notes to financial statements.

(English Translation of Financial Statements and Report Originally Issued in Chinese)

TOPCO SCIENTIFIC CO., LTD.**Statements of Changes in Equity****For the years ended December 31, 2025 and 2024****(Expressed in Thousands of New Taiwan Dollars)**

	Share capital		Retained earnings			Exchange differences on translation of foreign financial statements	Other equity		Total other equity	Total equity
	Ordinary shares	Certificate of entitlement to new shares from convertible bond	Capital surplus	Legal reserve	Unappropriated retained earnings		Unrealized gains (losses) on financial assets measured at fair value through other comprehensive income	Total other equity		
Balance at January 1, 2024	\$ 1,886,996	-	2,688,841	2,176,321	7,580,983	9,757,304	(90,453)	866,377	775,924	15,109,065
Profit for the year ended December 31, 2024	-	-	-	-	3,655,935	3,655,935	-	-	-	3,655,935
Other comprehensive income	-	-	-	-	(3,563)	(3,563)	137,335	319,949	457,284	453,721
Total comprehensive income	-	-	-	-	3,652,372	3,652,372	137,335	319,949	457,284	4,109,656
Appropriation and distribution of retained earnings:										
Legal reserve appropriated	-	-	-	280,585	(280,585)	-	-	-	-	-
Cash dividends of ordinary share	-	-	-	-	(1,698,296)	(1,698,296)	-	-	-	(1,698,296)
Other changes in capital surplus:										
Cash dividends from capital surplus	-	-	(188,700)	-	-	-	-	-	-	(188,700)
Changes in ownership interests in subsidiaries	-	-	1,244	-	-	-	-	-	-	1,244
Conversion of convertible bonds	18,546	4,851	414,856	-	-	-	-	-	-	438,253
Disposal of investments in equity instruments designated at fair value through other comprehensive income	-	-	-	-	49,105	49,105	-	(49,105)	(49,105)	-
Balance at December 31, 2024	1,905,542	4,851	2,916,241	2,456,906	9,303,579	11,760,485	46,882	1,137,221	1,184,103	17,771,222
Profit for the year ended December 31, 2025	-	-	-	-	4,180,447	4,180,447	-	-	-	4,180,447
Other comprehensive income	-	-	-	-	(1,839)	(1,839)	(27,968)	129,215	101,247	99,408
Total comprehensive income	-	-	-	-	4,178,608	4,178,608	(27,968)	129,215	101,247	4,279,855
Appropriation and distribution of retained earnings:										
Legal reserve appropriated	-	-	-	370,148	(370,148)	-	-	-	-	-
Cash dividends of ordinary share	-	-	-	-	(2,293,351)	(2,293,351)	-	-	-	(2,293,351)
Other changes in capital surplus:										
Conversion of convertible bonds	7,885	5,268	228,874	-	-	-	-	-	-	242,027
Balance at December 31, 2025	\$ 1,913,427	10,119	3,145,115	2,827,054	10,818,688	13,645,742	18,914	1,266,436	1,285,350	19,999,753

See accompanying notes to financial statements.

(English Translation of Financial Statements and Report Originally Issued in Chinese)
TOPCO SCIENTIFIC CO., LTD.

Statements of Cash Flows

For the years ended December 31, 2025 and 2024

(Expressed in Thousands of New Taiwan Dollars)

	2025	2024
Cash flows from (used in) operating activities:		
Profit before tax	\$ 4,954,160	4,240,024
Adjustments:		
Adjustments to reconcile profit:		
Depreciation expense	156,709	166,170
Amortization expense	12,771	15,375
Expected credit loss (gains)	4,617	1,096
Net gain on financial assets at fair value through profit or loss	(423,372)	(99,377)
Interest expense	47,417	66,625
Interest income	(12,649)	(10,583)
Dividend income	(95,555)	(74,299)
Share of profits of subsidiaries, associates and joint ventures accounted for using equity method	(2,026,973)	(2,175,924)
Loss on disposal of property, plant and equipment, net	2,529	2,647
Others	1,105	157
Total adjustments to reconcile profit	<u>(2,333,401)</u>	<u>(2,108,113)</u>
Changes in operating assets and liabilities:		
Changes in operating assets:		
Increase in notes and accounts receivable	(2,062,225)	(1,068,643)
Increase in inventories	(548,970)	(115,428)
Decrease in financial assets at fair value through profit or loss	912	2,503
Increase in other current assets	(46,825)	(32,060)
(Increase) decrease in other financial assets	(27,731)	3,205
Total changes in operating assets	<u>(2,684,839)</u>	<u>(1,210,423)</u>
Changes in operating liabilities:		
Increase in notes and accounts payable	2,261,098	909,039
Increase in contract liabilities	54,996	75,325
Increase in other current financial liabilities	231,636	225,705
Decrease in other current liabilities	(4,100)	(32,835)
(Decrease) increase in net defined benefit liabilities	(957)	480
Total changes in operating liabilities	<u>2,542,673</u>	<u>1,177,714</u>
Total changes in operating assets and liabilities	<u>(142,166)</u>	<u>(32,709)</u>
Total adjustments	<u>(2,475,567)</u>	<u>(2,140,822)</u>
Cash inflow generated from operations	2,478,593	2,099,202
Interest received	12,463	13,334
Interest paid	(39,205)	(52,771)
Dividends received	1,961,727	1,779,327
Income taxes paid	(659,070)	(673,921)
Net cash flows from operating activities	<u>3,754,508</u>	<u>3,165,171</u>
Cash flows from (used in) investing activities:		
Proceeds from disposal of financial assets at fair value through other comprehensive income	-	171,605
Proceeds from capital reduction of financial assets at fair value through profit or loss	1,939	16,932
Acquisition of financial assets at fair value through profit or loss	(49,672)	(60,418)
Proceeds from disposal of financial assets at fair valued through profit or loss	131,137	229,714
Acquisition of investments accounted for using equity method	(281,000)	(223,853)
Acquisition of property, plant and equipment	(413,641)	(4,224,247)
Proceeds from disposal of property, plant and equipment	-	89
Decrease (increase) in refundable deposits	86,920	(2,367)
Acquisition of intangible assets	(37,314)	(12,080)
(Increase) decrease in restricted assets	(4,154)	6,485
Reversal (payment) of remuneration to employees of subsidiaries	-	5,342
Increase in prepayments of land, buildings and equipments	-	(1,275)
Others	(6,219)	-
Net cash flows used in investing activities	<u>(572,004)</u>	<u>(4,094,073)</u>
Cash flows from (used in) financing activities:		
Decrease in short-term borrowings	(460,000)	(795,000)
Cash dividends paid	(2,293,351)	(1,886,996)
Addition of long-term borrowings	700,000	1,880,000
Repayments of long-term borrowings	(380,000)	(900,000)
Payment of lease liabilities	(52,057)	(66,733)
Net cash flows (used in) from financing activities	<u>(2,485,408)</u>	<u>(1,768,729)</u>
Net increase in cash and cash equivalents	697,096	(2,697,631)
Cash and cash equivalents at beginning of period	656,951	3,354,582
Cash and cash equivalents at end of period	<u>\$ 1,354,047</u>	<u>656,951</u>

See accompanying notes to financial statements.

(English Translation of Financial Statements and Report Originally Issued in Chinese)
TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements
For the years ended December 31, 2025 and 2024
(Expressed in Thousands of New Taiwan Dollars, Unless Otherwise Specified)

(1) Company history

TOPCO SCIENTIFIC CO., LTD. (the “Company”) was incorporated on February 17, 1990, as a company limited by shares and registered under the Ministry of Economic Affairs, R.O.C. The Company relocated to its new premises at 6F., No. 176, Zhouzi Street, Neihu District, Taipei City in October 2025. The Company engages in the trading of electronics products, high technology products and related materials and components, pollution prevention equipment; designing and installation of water purification and recycling systems, solar energy materials; providing solar energy system integration services and operation power of solar stations, as well as setting up a sport center that operates and provides sport training programs.

(2) Approval date and procedures of the financial statements

These financial statements were authorized for issuance by the Board of directors on March 10, 2026.

(3) New standards, amendments and interpretations adopted:

- (a) The impact of the IFRS Accounting Standards endorsed by the Financial Supervisory Commission, R.O.C. which have already been adopted.

The Company has initially adopted the following new amendments, which do not have a significant impact on its financial statements, from January 1, 2025:

- Amendments to IAS21 “Lack of Exchangeability”

- (b) The impact of IFRS Accounting Standards endorsed by the FSC but not yet effective

The Company assesses that the adoption of the following new amendments, effective for annual period beginning on January 1, 2026, would not have a significant impact on its financial statements:

- IFRS 17 “Insurance Contracts” and amendments to IFRS 17 “Insurance Contracts”
- Amendments to IFRS 9 and IFRS 7 “Amendments to the Classification and Measurement of Financial Instruments”
- Annual Improvements to IFRS Accounting Standards—Volume 11
- Amendments to IFRS 9 and IFRS 7 “Contracts Referencing Nature-dependent Electricity”

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

- (c) The impact of IFRS Accounting Standards issued by IASB but not yet endorsed by the FSC

The following new and amended standards, which may be relevant to the Company, have been issued by the International Accounting Standards Board (IASB), but have yet to be endorsed by the FSC:

Standards or Interpretations	Content of amendment	Effective date per IASB
IFRS 18 “Presentation and Disclosure in Financial Statements”	<p>The new standard introduces three categories of income and expenses, two income statement subtotals and one single note on management performance measures. The three amendments, combined with enhanced guidance on how to disaggregate information, set the stage for better and more consistent information for users, and will affect all the entities.</p> <ul style="list-style-type: none"> ● A more structured income statement: under current standards, companies use different formats to present their results, making it difficult for investors to compare financial performance across companies. The new standard promotes a more structured income statement, introducing a newly defined ‘operating profit’ subtotal and a requirement for all income and expenses to be allocated between three new distinct categories based on a company’s main business activities. ● Management performance measures (MPMs): the new standard introduces a definition for management performance measures, and requires companies to explain in a single note to the financial statements why the measure provides useful information, how it is calculated and reconcile it to an amount determined under IFRS Accounting Standards. ● Greater disaggregation of information: the new standard includes enhanced guidance on how companies group information in the financial statements. This includes guidance on whether information is included in the primary financial statements or is further disaggregated in the notes. 	January 1, 2027 note: On September 25, 2025, the FSC issued a press release announcing that Taiwan will adopt IFRS 18 beginning in 2028. Entities that need to adopt the new standard earlier may do with the endorsement of the FSC.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

The Company is evaluating the impact on its financial position and financial performance upon the initial adoption of the abovementioned standards or interpretations. The results thereof will be disclosed when the Company completes its evaluation.

The Company does not expect the following other new and amended standards, which have yet to be endorsed by the FSC, to have a significant impact on its financial statements:

- Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets Between an Investor and Its Associate or Joint Venture”
- IFRS 19 “Subsidiaries without Public Accountability: Disclosures” and amendments to IFRS 19 “Subsidiaries without Public Accountability: Disclosures”
- Amendments to IAS 21 “Translation to a Hyperinflationary Presentation Currency”

(4) Summary of material policies

The material accounting policies presented in the financial statements are summarized below. Except for those specifically indicated, the following accounting policies were applied consistently throughout the presented periods in the financial statements.

(a) Statement of compliance

These financial statements have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers.

(b) Basis of preparation

(i) Basis of measurement

Except for the following significant accounts, the financial statements have been prepared on the historical cost basis:

- 1) Financial instruments at fair value through profit or loss are measured at fair value;
- 2) Financial assets at fair value through other comprehensive income are measured at fair value; and
- 3) The defined benefit liabilities (assets) are measured at fair value of the plan assets, less the present value of the defined benefit obligation, limited as explained in note 4(p).

(ii) Functional and presentation currency

The functional currency of the Company is determined based on the primary economic environment in which the entities operate. The financial statements are presented in New Taiwan Dollars, which is the Company’s functional currency. All financial information presented in New Taiwan Dollars has been rounded to the nearest thousand.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

(c) Foreign currencies

(i) Foreign currency transactions

Transactions in foreign currencies are translated into the respective functional currencies of Company entities at the exchange rates at the dates of the transactions. At the end of each subsequent reporting period, monetary items denominated in foreign currencies are translated into the functional currencies using the exchange rate at that date. Non-monetary items denominated in foreign currencies that are measured at fair value are translated into the functional currencies using the exchange rate at the date that the fair value was determined. Non-monetary items denominated in foreign currencies that are measured based on historical cost are translated using the exchange rate at the date of the transaction.

Exchange differences are generally recognized in profit or loss, except for those differences relating to the following, which are recognized in other comprehensive income:

- 1) an investment in equity securities designated as at fair value through other comprehensive income;
- 2) a financial liability designated as a hedge of the net investment in a foreign operation to the extent that the hedge is effective; or
- 3) qualifying cash flow hedges to the extent the hedges are effective

(ii) Foreign operations

The assets and liabilities of foreign operations, including goodwill and fair value adjustments arising on acquisition, are translated into the presentation currency at the exchange rates at the reporting date. The income and expenses of foreign operations are translated into the presentation currency at the average rate. Exchange differences are recognized in other comprehensive income.

When a foreign operation is disposed of such that control, significant influence or joint control is lost, the cumulative amount in the translation reserve related to that foreign operation is reclassified to profit or loss as part of the gain or loss on disposal. When the Company disposes of any part of its interest in a subsidiary that includes a foreign operation while retaining control, the relevant proportion of the cumulative amount is reattributed to non-controlling interest. When the Company disposes of only part of investment in an associate of joint venture that includes a foreign operation while retaining significant or joint control, the relevant proportion of the cumulative amount is reclassified to profit or loss.

When the settlement of a monetary item receivable from or payable to a foreign operation is neither planned nor likely to occur in the foreseeable future, exchange difference arising from such a monetary item that are considered to form part of a net investment in the foreign operation are recognized in other comprehensive income.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

(d) Classification of current and non-current assets and liabilities

The Company classifies the asset as current under one of the following criteria, and all other assets are classified as non current.

- (i) It is expected to be realized, or intended to be sold or consumed, in the normal operating cycle;
- (ii) It is held primarily for the purpose of trading;
- (iii) It is expected to be realized within twelve months after the reporting period; or
- (iv) The asset is cash or a cash equivalent (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

The Company classifies the liability as current under one of the following criteria, and all other liabilities are classified as non current.

- (i) It is expected to be settled in the normal operating cycle;
- (ii) It is held primarily for the purpose of trading;
- (iii) It is due to be settled within twelve months after the reporting period; or
- (iv) The Company does not have the right at the end of the reporting period to defer settlement of the liability for at least twelve months after the reporting period.

(e) Cash and cash equivalents

Cash comprises cash on hand and demand deposits. Cash equivalents are short-term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

The time deposits which meet the above definition and are held for the purpose of meeting short-term cash commitments rather than for investment or other purposes are reclassified as cash equivalents.

(f) Financial instruments

Accounts receivables and debt securities issued are initially recognized when they are originated. All other financial assets and financial liabilities are initially recognized when the Company becomes a party to the contractual provisions of the instrument. A financial asset (unless it is an account receivable without a significant financing component) or financial liability is initially measured at fair value plus, for an item not at fair value through profit or loss (FVTPL), transaction costs that are directly attributable to its acquisition or issue. An account receivable without a significant financing component is initially measured at the transaction price.

(i) Financial assets

All regular way purchases or sales of financial assets are recognized and derecognized on a trade date basis.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

On initial recognition, a financial asset is classified as measured at: amortized cost; Fair value through other comprehensive income (FVOCI) – equity investment; or FVTPL. Financial assets are not reclassified subsequent to their initial recognition unless the Company changes its business model for managing financial assets, in which case all affected financial assets are reclassified on the first day of the first reporting period following the change in the business model.

1) Financial assets measured at amortized cost

A financial asset is measured at amortized cost if it meets both of the following conditions and is not designated as at FVTPL:

- it is held within a business model whose objective is to hold assets to collect contractual cash flows; and
- its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

These assets are subsequently measured at amortized cost, which is the amount at which the financial asset is measured at initial recognition, plus/minus, the cumulative amortization using the effective interest method, adjusted for any loss allowance. Interest income, foreign exchange gains and losses, as well as impairment, are recognized in profit or loss. Any gain or loss on derecognition is recognized in profit or loss.

2) Fair value through other comprehensive income (FVOCI)

On initial recognition of an equity investment that is not held for trading, the Company may irrevocably elect to present subsequent changes in the investment's fair value in other comprehensive income. This election is made on an instrument-by-instrument basis.

Equity investments at FVOCI are subsequently measured at fair value. Dividends are recognized as income in profit or loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognized in other comprehensive income and are never reclassified to profit or loss.

Dividend income is recognized in profit or loss on the date on which the Company's right to receive payment is established.

3) Fair value through profit or loss (FVTPL)

All financial assets not classified as amortized cost or FVOCI described as above are measured at FVTPL. On initial recognition, the Company may irrevocably designate a financial asset, which meets the requirements to be measured at amortized cost or at FVOCI, as at FVTPL if doing so eliminates or significantly reduces an accounting mismatch that would otherwise arise.

These assets are subsequently measured at fair value. Net gains and losses, including any interest or dividend income, are recognized in profit or loss.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

4) Impairment of financial assets

The Company recognizes loss allowances for expected credit losses (ECL) on financial assets measured at amortized cost (including cash and cash equivalents, amortized costs, notes and accounts receivable, other receivable, leases receivable, guarantee deposit paid and other financial assets), and contract assets.

The Company measures loss allowances at an amount equal to lifetime ECL, except for the following which are measured as 12-month ECL:

- debt securities that are determined to have low credit risk at the reporting date; and
- other debt securities and bank balances for which credit risk (i.e. the risk of default occurring over the expected life of the financial instrument) has not increased significantly since initial recognition.

Loss allowance for trade receivables and contract assets are always measured at an amount equal to lifetime ECL.

When determining whether the credit risk of a financial asset has increased significantly since initial recognition and when estimating ECL, the Company considers reasonable and supportable information that is relevant and available without undue cost or effort. This includes both quantitative and qualitative information and analysis based on the Company's historical experience and informed credit assessment as well as forward-looking information.

The Company assumes that the credit risk on a financial asset has increased significantly if it is more than 30 days past due.

The Company considers a financial asset to be in default when the financial asset is more than 90 days past due or the debtor is unlikely to pay its credit obligations to the Company in full.

The Company considers a debt security to have low credit risk when its credit risk rating is equivalent to the globally understood definition of 'investment grade which is considered to be BBB- or higher per Standard & Poor's, Baa3 or higher per Moody's or twA or higher per Taiwan Ratings'.

Lifetime ECLs are the ECLs that result from all possible default events over the expected life of a financial instrument.

12-month ECLs are the portion of ECLs that result from default events that are possible within the 12 months after the reporting date (or a shorter period if the expected life of the instrument is less than 12 months).

The maximum period considered when estimating ECLs is the maximum contractual period over which the Company is exposed to credit risk.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

ECLs, are a probability-weighted estimate of credit losses. Credit losses are measured as the present value of all cash shortfalls (i.e. the difference between the cash flows due to the Company in accordance with the contract and the cash flows that the Company expects to receive). ECLs are discounted at the effective interest rate of the financial asset.

At each reporting date, the Company assesses whether financial assets carried at amortized cost and debt securities at FVOCI are credit-impaired. A financial asset is “credit-impaired” when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred. Evidence that a financial asset is credit-impaired includes the following observable data:

- significant financial difficulty of the borrower or issuer;
- a breach of contract such as a default or being more than 90 days past due;
- the lender of the borrower, for economic or contractual reasons relating to the borrower's financial difficulty, having granted to the borrower a concession that the lender would not otherwise consider;
- it is probable that the borrower will enter bankruptcy or other financial reorganization;
or
- the disappearance of an active market for a security because of financial difficulties.

Loss allowances for financial assets measured at amortized cost are deducted from the gross carrying amount of the assets.

The gross carrying amount of a financial asset is written off when the Company has no reasonable expectations of recovering a financial asset in its entirety or a portion thereof. For corporate customers, the Company individually makes an assessment with respect to the timing and amount of write-off based on whether there is a reasonable expectation of recovery. The Company expects no significant recovery from the amount written off. However, financial assets that are written off could still be subject to enforcement activities in order to comply with the Company's procedures for recovery of amounts due.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

5) Derecognition of financial assets

The Company derecognizes a financial asset when the contractual rights to the cash flows from the financial asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all of the risks and rewards of ownership of the financial asset are transferred or in which the Company neither transfers nor retains substantially all of the risks and rewards of ownership and it does not retain control of the financial asset.

The Company enters into transactions whereby it transfers assets recognized in its statement of balance sheet, but retains either all or substantially all of the risks and rewards of the transferred assets. In these cases, the transferred assets are not derecognized.

(ii) Financial liabilities and equity instruments

1) Classification of debt or equity

Debt and equity instruments issued by the Company are classified as financial liabilities or equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument.

2) Equity instrument

An equity instrument is any contract that evidences residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued are recognized as the amount of consideration received, less the direct cost of issuing.

3) Compound financial instruments

Compound financial instruments issued by the Company comprise convertible bonds denominated in NTD that can be converted to ordinary shares at the option of the holder, when the number of shares to be issued is fixed and does not vary with changes in fair value.

The liability component of compound financial instruments is initially recognized at the fair value of a similar liability that does not have an equity conversion option. The equity component is initially recognized at the difference between the fair value of the compound financial instrument as a whole and the fair value of the liability component. Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts.

Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortized cost using the effective interest method. The equity component of a compound financial instrument is not remeasured.

Interest related to the financial liability is recognized in profit or loss. On conversion at maturity, the financial liability is reclassified to equity and no gain or loss is recognized.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

4) Financial liabilities

Financial liabilities are classified as measured at amortized cost or FVTPL. A financial liability is classified as at FVTPL if it is classified as held-for-trading, it is a derivative or it is designated as such on initial recognition. Financial liabilities at FVTPL are measured at fair value and net gains and losses, including any interest expense, are recognized in profit or loss.

Other financial liabilities are subsequently measured at amortized cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss on derecognition is also recognized in profit or loss.

5) Derecognition of financial liabilities

The Company derecognizes a financial liability when its contractual obligations are discharged, cancelled or expired. The Company also derecognizes a financial liability when its terms are modified and the cash flows of the modified liability are substantially different, in which case a new financial liability based on the modified terms is recognized at fair value.

On derecognition of a financial liability, the difference between the carrying amount of a financial liability extinguished and the consideration paid (including any non-cash assets transferred, or liabilities assumed) is recognized in profit or loss.

6) Offsetting of financial assets and liabilities

Financial assets and financial liabilities are offset, and the net amount presented in the statement of balance sheet when, and only when, the Company currently has a legally enforceable right to set off the amounts and it intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously.

(g) Inventories

Inventories are measured at the lower of cost and net realizable value. The cost of inventories is based on the weighted-average-cost principle and includes expenditure incurred in acquiring the inventories, production or conversion costs, and other costs incurred in bringing them to their present location and condition. In the case of manufactured inventories and work in progress, cost includes an appropriate share of production overheads based on normal operating capacity.

Net realizable value is the estimated selling price in the ordinary course of business, less, the estimated costs of completion and selling expenses.

(h) Investment in associates

Associates are those entities in which the Company has significant influence, but not control, over the financial and operating policies.

Investments in associates are accounted for using the equity method and are recognized initially at cost. The cost of the investment includes transaction costs. The carrying amount of the investment in associates includes goodwill arising from the acquisition, less, any accumulated impairment losses.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

The financial statements include the Company's share of the profit or loss and other comprehensive income of those associates, after adjustments to align their accounting policies with those of the Company, from the date on which significant influence commences until the date on which significant influence ceases. The Company recognizes any changes of its proportionate share in the investee within capital surplus, when an associate's equity changes due to reasons other than profit and loss or comprehensive income, which did not result in changes in actual significant influence.

Gains and losses resulting from transactions between the Company and an associate are recognized only to the extent of unrelated Company's interests in the associate.

When the Company's share of losses of an associate equals or exceeds its interests in an associate, it discontinues recognizing its share of further losses. After the recognized interest is reduced to zero, additional losses are provided for, and a liability is recognized, only to the extent that the Company has incurred legal or constructive obligations or made payments on behalf of the associate.

When the Company subscribes to additional shares in an associate at a percentage different from its existing ownership percentage, the resulting carrying amount of the investment will differ from the amount of the Company's proportionate interest in the net assets of the associate. The Company records such a difference as an adjustment to investments with the corresponding amount charged or credited to capital surplus. The aforesaid adjustment should first be adjusted under capital surplus. If the capital surplus resulting from changes in ownership interest is not sufficient, the remaining difference is debited to retained earnings. If the Company's ownership interest is reduced due to the additional subscription to the shares of the associate by other investors, the proportionate amount of the gains or losses previously recognized in other comprehensive income in relation to that associate will be reclassified to profit or loss on the same basis as would be required if the associate had directly disposed of the related assets or liabilities.

(i) Investment in subsidiary

When preparing parent-company-only financial statements, investment in subsidiaries which are controlled by the Company is accounted for using the equity method. Under the equity method, the amounts of net income, other comprehensive income and equity attributable to shareholders of the Company in the parent-company-only financial statements are equal to those in the consolidated financial statements.

Changes in the Company's ownership interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions.

(j) Property, plant and equipment

(i) Recognition and measurement

Items of property, plant and equipment are measured at cost, which includes capitalized borrowing cost, less accumulated depreciation and accumulated impairment losses.

If significant parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment.

Any gain or loss on disposal of an item of property, plant and equipment is recognized in profit or loss.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

(ii) Subsequent cost

Subsequent expenditure is capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Company.

(iii) Depreciation

Depreciation is calculated on the cost of an asset less its residual value and is recognized in profit or loss on a straight-line basis over the estimated useful lives of each component of an item of property, plant and equipment.

Land is not depreciated.

The estimated useful lives of property, plant and equipment for current and comparative periods are as follows:

- 1) Buildings: 3~60 years
- 2) Building improvement: 2~10 years
- 3) Machine and others: 2~30 years

Depreciation methods, useful lives, and residual values are reviewed at each reporting date and adjusted if appropriate.

(k) Lease

At inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

(i) As a lessee

The Company recognizes a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received.

The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be reliably determined, the Company's incremental borrowing rate. Generally, the Company uses its incremental borrowing rate as the discount rate.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

Lease payments included in the measurement of the lease liability comprise the following:

- fixed payments, including in-substance fixed payments;
- variable lease payments that depend on an index or a rate, initially measured using the index or rate as at the commencement date;
- amounts expected to be payable under a residual value guarantee; and
- payments for purchase or termination options that are reasonably certain to be exercised.

The lease liability is measured at amortized cost using the effective interest method. It is remeasured when:

- there is a change in future lease payments arising from the change in an index or rate; or
- there is a change in the Company's estimate of the amount expected to be payable under a residual value guarantee; or
- there is a change in the lease term resulting from a change of its assessment on whether it will exercise an option to purchase the underlying asset, or
- there is a change of its assessment on whether it will exercise an extension or termination option; or
- there is any lease modifications

When the lease liability is remeasured, other than lease modifications, a corresponding adjustment is made to the carrying amount of the right-of-use asset, or in profit and loss if the carrying amount of the right-of-use asset has been reduced to zero.

When the lease liability is remeasured to reflect the partial or full termination of the lease for lease modifications that decrease the scope of the lease, the Company accounts for the remeasurement of the lease liability by decreasing the carrying amount of the right-of-use asset to reflect the partial or full termination of the lease, and recognize in profit or loss any gain or loss relating to the partial or full termination of the lease.

The Company presents right-of-use assets that do not meet the definition of investment and lease liabilities as a separate line item respectively in the statement of financial position.

The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less and leases of low-value — assets,, including office equipment, IT equipment and other equipment. The Company recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

(ii) As a lessor

When the Company acts as a lessor, it determines at lease commencement whether each lease is a finance lease or an operating lease. To classify each lease, the Company makes an overall assessment of whether the lease transfers to the lessee substantially all of the risks and rewards of ownership incidental to ownership of the underlying asset. If this is the case, then the lease is a finance lease; if not, then the lease is an operating lease. As part of this assessment, the Company considers certain indicators such as whether the lease is for the major part of the economic life of the asset.

When the Company is an intermediate lessor, it accounts for its interests in the head lease and the sub-lease separately. It assesses the lease classification of a sub-lease with reference to the right-of-use asset arising from the head lease. If a head lease is a short-term lease to which the Company applies the exemption described above, then it classifies the sub-lease as an operating lease.

If an arrangement contains lease and non-lease components, the Company applies IFRS15 to allocate the consideration in the contract.

(l) Intangible assets

(i) Recognition and measurement

Intangible assets that are acquired by the Company and have finite useful lives are measured at cost, less accumulated amortization and any accumulated impairment losses.

(ii) Subsequent expenditure

Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All other expenditure, including expenditure on internally generated goodwill and brands, is recognized in profit or loss as incurred.

(iii) Amortization

Amortization is calculated over the cost of the asset, less its residual value, and is recognized in profit or loss on a straight-line basis over the estimated useful lives of intangible assets, other than goodwill, from the date that they are available for use.

The estimated useful lives for the current and comparative periods are as follows:

- 1) Computer software: 1~5 years
- 2) Right of using: the contract period

Amortization methods, useful lives and residual values are reviewed at each reporting date and adjusted if appropriate.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

(m) Impairment of non-financial assets

At each reporting date, the Company reviews the carrying amounts of its non-financial assets (other than inventories, contract assets, deferred tax assets) to determine whether there is any indication of impairment. If any such indication exists, then the asset's recoverable amount is estimated.

For impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or CGUs.

The recoverable amount of an asset or CGU is the greater of its value in use and its fair value less costs to sell.

An impairment loss is recognized if the carrying amount of an asset or CGU exceeds its recoverable amount. Impairment losses are recognized in profit or loss.

An impairment loss in respect of goodwill is not reversed. For other assets, an impairment loss is reversed only to the extent that the asset's carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized.

(n) Provisions

A provision is recognized if, as a result of a past event, the Company has a present obligation that can be estimated reliably, and it is probably that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects the current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognized as finance cost.

(o) Revenue from contracts with customers

Revenue is measured based on the consideration to which the Company expects to be entitled in exchange for transferring goods or services to a customer. The Company recognizes revenue when it satisfies a performance obligation by transferring control of a good or a service to a customer. The accounting policies for the Company's main types of revenue are explained below.

(i) Sale of goods

The Company sells of semiconductor material and electronic material. The Company recognizes revenue when control of the products has transferred, being when the products are delivered to the customer, the customer has full discretion over the channel and price to sell the products, and there is no unfulfilled obligation that could affect the customer's acceptance of the products. Delivery occurs when the products have been shipped to the specific location, the risks of obsolescence and loss have been transferred to the customer, and either the customer has accepted the products in accordance with the sales contract, the acceptance provisions have lapsed, or the Company has objective evidence that all criteria for acceptance have been satisfied.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

The Company provides volume rebates to customers that based on accumulated sales for each month or each quarter. Revenue from these sales is recognized based on the price specified in the contract, net of the estimated volume discounts. Accumulated experience is used to estimate the discounts, using the expected value method, and revenue is only recognized to the extent that it is highly probable that a significant reversal will not occur. A refund liability is recognized for expected volume discounts payable to customers in relation to sales made until the end of the reporting period.

A receivable is recognized when the goods are delivered as this is the point in time that the Company has a right to an amount of consideration that is unconditional.

(ii) Commissions

When the Company acts in the capacity of an agent rather than as the principal in a transaction, the revenue is net amount of commission made by the Company.

(iii) Financing components

The Company does not expect to have any contracts where the period between the transfer of the promised goods or services to the customer and payment by the customer exceeds one year. As a consequence, the Company does not adjust any of the transaction prices for the time value of money.

(p) Employee benefits

(i) Defined contribution plans

Obligations for contributions to defined contribution plans are expensed as the related service is provided.

(ii) Defined benefit plans

The Company's net obligation in respect of defined benefit plans is calculated separately for each the plan by estimating the amount of future benefit that employees have earned in the current and prior periods, discounting that amount and deducting the fair value of any plan assets.

The calculation of defined benefit obligations is performed annually by a qualified actuary using the projected unit credit method. When the calculation results in a potential asset for the Company, the recognized asset is limited to the present value of economic benefits available in the form of any future refunds from the plan or reductions in future contributions to the plan. To calculate the present value of economic benefits, consideration is given to any applicable minimum funding requirements.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

Remeasurements of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the asset ceiling (if any, excluding interest), are recognized immediately in other comprehensive income, and accumulated in retained earnings within equity. The Company determines the net interest expense (income) on the net defined benefit liability (asset) for the period by applying the discount rate used to measure the defined benefit obligation at the beginning of the annual period to the then-net defined benefit liability (asset). Net interest expense and other expenses related to defined benefit plans are recognized in profit or loss.

When the benefits of a plan are changed or when a plan is curtailed, the resulting change in benefit that relates to past service or the gain or loss on curtailment is recognized immediately in profit or loss. The Company recognizes gains and losses on the settlement of a defined benefit plan when the settlement occurs.

(iii) Short-term employee benefits

Short-term employee benefit is expensed as the related service is provided.

A liability is recognized for the amount expected to be paid if the Company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.

(q) Share-based payment

The grant-date fair value of equity-settled share-based payment arrangements granted to employees is generally recognized as an expense, with a corresponding increase in equity, over the vesting period of the awards. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognized is based on the number of awards that meet the related service and non-market performance conditions at the vesting date.

For share-based payment awards with non-vesting conditions, the grant-date fair value of the share-based payment is measured to reflect such conditions, and there is no true-up for differences between expected and actual outcomes.

(r) Income taxes

Income taxes comprise current taxes and deferred taxes. Except for expenses related to business combinations or recognized directly in equity or other comprehensive income, all current and deferred taxes are recognized in profit or loss.

The Company has determined that the global minimum top-up tax - which it is required to pay under Pillar Two legislation - is an income tax in the scope of IAS 12. The Company has applied a temporary mandatory relief from deferred tax accounting for the impacts of the top-up tax and accounts for it as a current tax when it is incurred.

Current taxes comprise the expected tax payables or receivables on the taxable profits (losses) for the year and any adjustment to the tax payable or receivable in respect of previous years. The amount of current tax payables or receivables are the best estimate of the tax amount expected to be paid or received. It is measured using tax rates enacted or substantively enacted at the reporting date.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

Deferred taxes arise due to temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and their respective tax bases. Deferred taxes are recognized except for the following:

- (i) temporary differences on the initial recognition of assets and liabilities in a transaction that is not a business combination and at the time of the transaction (i) affects neither accounting nor taxable profits (losses) and (ii) does not give rise to equal taxable and deductible temporary differences;
- (ii) temporary differences related to investments in subsidiaries, associates and joint arrangements to the extent that the Company is able to control the timing of the reversal of the temporary differences and it is probable that they will not reverse in the foreseeable future; and
- (iii) taxable temporary differences arising on the initial recognition of goodwill.

Deferred taxes are measured at tax rates that are expected to be applied to temporary differences when they reverse, using tax rates enacted or substantively enacted at the reporting date.

Deferred tax assets and liabilities are offset if the following criteria are met:

- (i) the Company has a legally enforceable right to set off current tax assets against current tax liabilities; and
- (ii) the deferred tax assets and the deferred tax liabilities relate to income taxes levied by the same taxation authority on either:
 - 1) the same taxable entity; or
 - 2) different taxable entities which intend to settle current tax assets and liabilities on a net basis, or to realize the assets and liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.

The 5% surtax on the Company's unappropriated earnings is recorded as current tax expense in the following year after the resolution to appropriate retained earnings is approved in a stockholders' meeting.

- (s) Earnings per share

The Company discloses the Company's basic and diluted earnings per share attributable to ordinary shareholders of the Company. Basic earnings per share is calculated as the profit attributable to the ordinary shareholders of the Company divided by weighted average number of ordinary shares outstanding. Diluted earnings per share is calculated as the profit attributable to ordinary shareholders of the Company divided by weighted average number of ordinary shares outstanding after adjustment for the effects of all dilutive potential ordinary shares. Dilutive potential ordinary shares comprise convertible bonds and employee compensation not yet approved by the Board of directors.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

(t) Operating segments

The operating segment information is disclosed in the consolidated financial statements. Therefore, the Company will not disclose the operating segment information in the parent-company-only financial statements.

(5) Significant accounting assumptions and judgments, and major sources of estimation uncertainty:

In preparing these financial statements, management has made judgments and estimates about the future, including climate-related risks and opportunities, that affect the application of the accounting policies and the reported amount of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis and are consistent with the Company's risk management and climate-related commitments where appropriate. Revisions to estimates are recognized prospectively in the period of the change and future periods.

There are no critical judgments in applying accounting policies that have significant effect on amount recognized in the financial statements.

(6) Explanation of significant accounts:

(a) Cash and cash equivalents

	December 31, 2025	December 31, 2024
Cash on hand	\$ 2,255	2,286
Checking accounts and demand deposits	1,053,207	375,992
Time deposits	298,585	278,673
	<u>\$ 1,354,047</u>	<u>656,951</u>

Please refer to note 6(v) for the disclosure of the exchange rate risk and the sensitivity analysis of the financial assets and liabilities of the Company.

(b) Financial assets and liabilities at fair value through profit or loss

	December 31, 2025	December 31, 2024
Mandatorily measured at fair value through profit or loss:		
Domestic listed stocks	98,774	133,260
Foreign listed stocks	175,964	72,406
Unlisted stocks and limited partnership	526,455	257,979
Foreign unlisted funds	28,471	26,580
Convertible bonds-embedded derivatives	27	410
	<u>\$ 829,691</u>	<u>490,635</u>
Current	\$ 27	-
Non-current	829,664	490,635
	<u>\$ 829,691</u>	<u>490,635</u>

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

The gain or loss on valuation of financial assets at fair value of the Company for the years ended December 31, 2025 and 2024, was a gain of \$423,372, and a gain of \$99,377, respectively.

- (i) During the years ended December 31, 2025 and 2024, the dividends of \$9,964 and \$8,414, respectively, related to mandatorily measured at fair value through profit or loss held on the years then ended, were recognized as other income by the Company, please refer to note 6(u).
- (ii) The Company's information of market risk, please refer to note 6(v).
- (iii) The Company's information of convertible bonds-embedded derivatives, please refer to note 6(m).
- (iv) As of December 31, 2025 and 2024, the Company did not provide financial assets as collateral for its loans.

(c) Non-current financial assets at fair value through other comprehensive income

	December 31, 2025	December 31, 2024
Equity investments at fair value through other comprehensive income		
Domestic listed stocks	\$ 169,575	159,885
Domestic unlisted stocks	1,436,590	1,325,865
	\$ 1,606,165	1,485,750

The Company designated the investments shown above as equity securities as at fair value through other comprehensive income because these equity securities represent those investments that the Company intends to hold for long term strategic purposes.

The Company sold part of the stocks designated as at fair value through other comprehensive income in 2024. The stocks sold had a fair value of \$171,605, and the Company transferred the foregoing cumulative gain on disposal of \$49,105 from other equity to retained earnings.

During the years ended December 31, 2025 and 2024, the dividends of \$85,591 and \$65,885, respectively, related to equity securities as at fair value through other comprehensive income held on the years then ended, were recognized as other income by the Company, please refer to note 6(u).

During the years ended December 31, 2025 and 2024, the Company's unrealized gain or loss on valuation of financial assets at fair value through other comprehensive income was a gain of \$120,415 and a gain of \$338,188, respectively.

The Company's information of market risk, please refer to note 6(v).

As of December 31, 2025 and 2024, the Company did not provide financial assets as collateral for its loans.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

(d) Notes and accounts receivable

	December 31, 2025	December 31, 2024
Notes receivable from operating activities	\$ 2,087	3,001
Accounts receivable from measured as amortized cost	6,292,375	4,229,236
Less: loss allowance	<u>10,112</u>	<u>5,495</u>
	<u>\$ 6,284,350</u>	<u>4,226,742</u>
Notes and accounts receivable, net	<u>\$ 6,102,466</u>	<u>4,054,037</u>
Notes and accounts receivable due from related parties, net	<u>\$ 181,884</u>	<u>172,705</u>

The Company applies the simplified approach to provide for its expected credit losses, i.e. the use of lifetime expected loss provision for all receivables. To measure the expected credit losses, notes and accounts receivables have been grouped based on shared credit risk characteristics and the days past due according to the historical credit loss experience as well as incorporated forward looking information, such as the reasonable prediction of future economic situation. The loss allowance provisions were determined as follows:

	December 31, 2025		
	Gross carrying amount	Weighted- average loss rate	Loss allowance provision
Current	\$ 5,932,889	0.10%	5,640
Overdue 0-30 days	324,907	1.00%	3,249
Overdue 31-60 days	33,718	3.00%	1,012
Overdue 61-90 days	1,678	5.00%	84
Overdue over 91 days	<u>1,270</u>	10.00%	<u>127</u>
	<u>\$ 6,294,462</u>		<u>10,112</u>
	December 31, 2024		
	Gross carrying amount	Weighted- average loss rate	Loss allowance provision
Current	\$ 4,091,028	0.10%	3,877
Overdue 0-30 days	135,570	1.00%	1,356
Overdue 31-60 days	4,316	3.00%	130
Overdue over 91 days	<u>1,323</u>	10.00%	<u>132</u>
	<u>\$ 4,232,237</u>		<u>5,495</u>

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

The movement in the allowance for notes and accounts receivable were as follows:

	2025	2024
Balance at January 1	\$ 5,495	4,399
Impairment loss recognized	4,617	1,096
Balance at December 31	<u>\$ 10,112</u>	<u>5,495</u>

(e) Inventories

	December 31, 2025	December 31, 2024
Merchandise inventories	\$ 2,713,157	2,195,486
Goods in transit	81,846	50,547
	<u>\$ 2,795,003</u>	<u>2,246,033</u>

The details of the cost of sales were as follows:

	2025	2024
Cost of sales	\$ 35,623,653	26,951,709
Provision (reversal) for inventory valuation loss and obsolescence	9,850	1,587
Loss on indemnity of inventory and others	9,111	(259)
	<u>\$ 35,642,614</u>	<u>26,953,037</u>

As of December 31, 2025 and 2024, the Company did not provide inventories as collateral for its loans.

(f) Investments accounted for using equity method

The Company's financial information for investments accounted for using equity method on the reporting date was as follows:

	December 31, 2025	December 31, 2024
Subsidiaries	\$ 7,389,494	7,191,988
Associates	2,840,280	2,622,145
	<u>\$ 10,229,774</u>	<u>9,814,133</u>

(i) Subsidiaries

Please refer to the consolidated financial statements for the year ended December 31, 2025.

During the years ended December 31, 2025 and 2024, the share of profits of subsidiaries accounted for using equity method amounted to \$1,501,406 and \$1,562,842, respectively.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

(ii) Associates

The Company's financial information for associates accounted for using the equity method, which are individually insignificant, was as follows:

	<u>December 31,</u> <u>2025</u>	<u>December 31,</u> <u>2024</u>
The carrying amount of individually insignificant associates' equity	<u>\$ 2,840,280</u>	<u>2,622,145</u>
	<u>2025</u>	<u>2024</u>
Attributable to the Company:		
Profit from continuing operations	\$ 525,567	613,082
Other comprehensive income	-	182
Total comprehensive income	<u>\$ 525,567</u>	<u>613,264</u>

(iii) As of December 31, 2025 and 2024, the Company did not provide any investments accounted for using equity method as collaterals for its loans.

(g) Changes in ownership of subsidiaries

- (i) The Company acquired 77.06% of the shares of its subsidiary Unitech New Energy Engineering in 2021. According to the share purchase agreements, if Unitech New Energy Engineering's net profit meets the certain criteria in 2021 and 2022, the Company will pay \$20,888 at the settlement expiration of one year and two years to Unitech New Energy Engineering, respectively, totaling \$41,776. The investment payment amounting to \$20,888 and \$12,824 had been paid by the Company for the years ended December 31, 2023 and 2022, as of December 31, 2025, resulting in the remaining amount of \$8,064 to be recognized as accrued expenses and other payables in the balance sheet.
- (ii) The associated company, Top Energy Innovation Corporation, which was accounted for using the equity method, disposed of its 100% equity interest in July 2025. Due to the disposal of the shares, the net value of the equity of Topco Investment that held by the Company decrease \$3.
- (iii) The associated company, YAO YUE ENERGY, which was accounted for using the equity method, disposed of its 100% equity interest in April 2025. Due to the disposal of the shares, the net value of the equity of Topco International Investment that held by the Company decrease \$405.
- (iv) In April and July 2025, the Company's subsidiary, Jia Yi Energy, acquired 100% equity interests in YAO YUE ENERGY and Top Energy Innovation Corporation, respectively, both associates accounted for using the equity method, resulting in an increase of NT\$408 in the net value of the equity of Jia Yi Energy to the Company.
- (v) The associate of the Company, Fei Da Intelligent, which was accounted for using the equity method, increased capital and issued new shares in 2024. Due to the acquisition of new shares at a non-shareholding ratio, the net value of equity of Topco Investment that held by the Company decreased \$15 for the year ended December 31, 2024.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

- (vi) The associate of the Company, Tai Ying Resource, which was accounted for using the equity method, increased capital and issued new shares in fourth quarter of 2024. Due to the acquisition of new shares at a non-shareholding ratio, the net value of equity of Chien Yueh that held by the Company decreased \$151 for the year ended December 31, 2024.
- (vii) The associate of the Company, Tai Ying Resource, which was accounted for using the equity method, increased capital and issued new shares in fourth quarter of 2024. Due to the acquisition of new shares at a non-shareholding ratio, the net value of equity of Topco International Investment that held by the Company increased \$1,410 for the year ended December 31, 2024.
- (viii) In summary, the above capital surplus increased by \$0 and increased by \$1,244 for the years ended December 31, 2025 and 2024, respectively, due to the above transaction.

(h) Property, plant and equipment

The cost, depreciation, and impairment of the property, plant and equipment of the Company for the years ended December 31, 2025 and 2024 were as follows:

	Land	Buildings and building improvement	Machinery and others	Construction in progress and equipment to be inspected	Total
Cost:					
Balance at January 1, 2025	\$ 4,082,792	3,302,283	515,296	371,189	8,271,560
Additions	-	263,386	147,836	3,166	414,388
Disposals	-	(15,052)	(70,099)	-	(85,151)
Reclassifications	-	198,037	31,535	(230,713)	(1,141)
Balance at December 31, 2025	<u>\$ 4,082,792</u>	<u>3,748,654</u>	<u>624,568</u>	<u>143,642</u>	<u>8,599,656</u>
Balance at January 1, 2024	\$ 671,773	1,378,466	554,096	141,111	2,745,446
Additions	2,558,919	1,401,551	19,304	244,473	4,224,247
Disposals	-	(4,467)	(68,810)	-	(73,277)
Reclassifications	852,100	526,733	10,706	(14,395)	1,375,144
Balance at December 31, 2024	<u>\$ 4,082,792</u>	<u>3,302,283</u>	<u>515,296</u>	<u>371,189</u>	<u>8,271,560</u>
Depreciation and impairments loss:					
Balance at January 1, 2025	\$ -	374,490	245,036	-	619,526
Depreciation	-	53,154	53,288	-	106,442
Disposals	-	(15,052)	(67,570)	-	(82,622)
Balance at December 31, 2025	<u>\$ -</u>	<u>412,592</u>	<u>230,754</u>	<u>-</u>	<u>643,346</u>
Balance at January 1, 2024	\$ -	339,209	251,021	-	590,230
Depreciation	-	39,748	60,089	-	99,837
Disposals	-	(4,467)	(66,074)	-	(70,541)
Balance at December 31, 2024	<u>\$ -</u>	<u>374,490</u>	<u>245,036</u>	<u>-</u>	<u>619,526</u>
Carrying amounts:					
Balance at December 31, 2025	<u>\$ 4,082,792</u>	<u>3,336,062</u>	<u>393,814</u>	<u>143,642</u>	<u>7,956,310</u>
Balance at January 1, 2024	<u>\$ 671,773</u>	<u>1,039,257</u>	<u>303,075</u>	<u>141,111</u>	<u>2,155,216</u>
Balance at December 31, 2024	<u>\$ 4,082,792</u>	<u>2,927,793</u>	<u>270,260</u>	<u>371,189</u>	<u>7,652,034</u>

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

In order to accommodate business development and ensure corporate sustainable operation, the Board of Directors resolved to purchase an office building on Zhousi Street in Neihu, for a total contract price of \$5,350,000. The Company completed the transfer registration in March 2024.

As of December 31, 2025 and 2024, the Company provided property, plant and equipment as collateral for its long-term loans. Please refer to Note 8.

(i) Right-of-use assets

The Company leases many assets including land, buildings, vehicles and equipment. Information about leases for which the Company as a lessee is presented below:

	<u>Land</u>	<u>Buildings</u>	<u>Vehicles</u>	<u>Machinery</u>	<u>Total</u>
Cost:					
Balance at January 1, 2025	\$ 4,979	115,501	68,875	4,941	194,296
Additions	2,507	53,469	17,668	-	73,644
Disposals	-	(60,921)	(14,753)	(4,941)	(80,615)
Balance at December 31, 2025	<u>\$ 7,486</u>	<u>108,049</u>	<u>71,790</u>	<u>-</u>	<u>187,325</u>
Balance at January 1, 2024	\$ 6,624	150,187	74,946	4,941	236,698
Additions	-	26,858	16,810	-	43,668
Disposals	(1,645)	(61,544)	(22,881)	-	(86,070)
Balance at December 31, 2024	<u>\$ 4,979</u>	<u>115,501</u>	<u>68,875</u>	<u>4,941</u>	<u>194,296</u>
Depreciation:					
Balance at January 1, 2025	\$ 524	65,821	37,409	4,132	107,886
Depreciation	889	28,919	19,650	809	50,267
Disposals	-	(57,784)	(14,753)	(4,941)	(77,478)
Balance at December 31, 2025	<u>\$ 1,413</u>	<u>36,956</u>	<u>42,306</u>	<u>-</u>	<u>80,675</u>
Balance at January 1, 2024	\$ 1,778	82,234	39,397	3,161	126,570
Depreciation	391	45,100	19,871	971	66,333
Disposals	(1,645)	(61,513)	(21,859)	-	(85,017)
Balance at December 31, 2024	<u>\$ 524</u>	<u>65,821</u>	<u>37,409</u>	<u>4,132</u>	<u>107,886</u>
Carrying amount:					
Balance at December 31, 2025	<u>\$ 6,073</u>	<u>71,093</u>	<u>29,484</u>	<u>-</u>	<u>106,650</u>
Balance at January 1, 2024	<u>\$ 4,846</u>	<u>67,953</u>	<u>35,549</u>	<u>1,780</u>	<u>110,128</u>
Balance at December 31, 2024	<u>\$ 4,455</u>	<u>49,680</u>	<u>31,466</u>	<u>809</u>	<u>86,410</u>

(j) Other financial assets and other non-current assets

(i) The other current financial assets of the Company were as follows:

	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Restricted assets	\$ 8,817	5,163
Other receivables	35,284	7,367
	<u>\$ 44,101</u>	<u>12,530</u>

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

The restricted time deposits to be used for sport training courses had been collected in advance. Please refer to note 8.

- (ii) The other non-current assets of the Company were as follows:

	December 31, 2025	December 31, 2024
Prepayments of equipments	\$ -	1,275
Restricted assets	2,380	1,880
Refundable deposits	113,483	200,403
Computer software cost and others	61,671	30,909
	<u>\$ 177,534</u>	<u>234,467</u>

As of December 31, 2025 and 2024, the Company did provide any increase in restricted assets as collateral for its loan, please refer to note 8.

- (k) Short-term borrowings

The short-term borrowings of the Company were as follows:

	December 31, 2025	December 31, 2024
Unsecured bank loans	<u>\$ -</u>	<u>460,000</u>
Unused credit lines	<u>\$ 6,036,747</u>	<u>6,465,158</u>
Range of interest rates	<u>-</u>	<u>1.68%~1.87%</u>

- (i) For information on the Company's interest risk, foreign currency risk and liquidity risk, please refer to note 6(v).

- (ii) The Company did not provide any assets as collaterals for its loans.

- (l) Long-term borrowings

The details were as follows:

	December 31, 2025			
	Currency	Rate	Maturity year	Amount
Unsecured bank loans	NTD	1.88%	2028.07	\$ 700,000
Secured bank loans	NTD	2.12%	2044.01	1,200,000
Less: current portion				<u>-</u>
Total				<u>\$ 1,900,000</u>
Unused credit lines				<u>\$ 300,000</u>

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

	December 31, 2024			
	Currency	Rate	Maturity year	Amount
Unsecured bank loans	NTD	1.69%~1.88%	2027.10	\$ 300,000
Secured bank loans	NTD	2.00%~2.12%	2044.1	1,280,000
Less: current portion				-
Total				\$ 1,580,000
Unused credit lines				\$ 600,000

- (i) The Company issued new loans amounted to \$700,000 and \$1,880,000 in 2025 and 2024, respectively. The repayments amounted to \$380,000 and \$900,000 in 2025 and 2024, respectively.
- (ii) For information on the Company's interest risk, foreign currency risk and liquidity risk, please refer to note 6(v).
- (iii) For the collateral for long-term borrowings, please refer to note 8.
- (m) Convertible bonds payable
- (i) The Company issued the second domestic unsecured convertible bonds with the face values of \$1,000,000 on June 29, 2023 as follows:

	December 31, 2025	December 31, 2024
Total convertible corporate bonds issued	\$ 1,000,000	1,000,000
Cumulative converted amount	(695,600)	(450,900)
Unamortized discounted corporate bonds payable	(5,983)	(15,476)
	298,417	533,624
Unamortized issuing costs of corporate bonds payable	(339)	(878)
Corporate bonds issued balance at year-end	\$ 298,078	532,746
Embedded derivatives – call option, include in current financial assets at fair value through profit or loss	\$ 27	-
Embedded derivatives – call option, include in non-current financial assets at fair value through profit or loss	\$ -	410
Equity component – conversion rights, include in capital surplus	\$ 17,967	32,411
	2025	2024
Embedded derivatives – call option, gains or losses at fair value, include in gain (losses) on financial assets (liabilities) at fair value through profit or loss	\$ (383)	410
Interest expenses	\$ (7,368)	(14,196)

The effective rates of the second unsecured convertible bonds payable was 1.7919%.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

The significant terms of the aforementioned convertible bonds were as follow as:

- 1) Interest rate: 0%
- 2) Duration: Three years(June 29,2023 to June 29,2026)
- 3) Redemption methods

Within the period between three month after the issuance date and 40 days before the last convertible date, if the closing price of the Company's ordinary shares on the TWSE for a period of 30 consecutive trading days before redemption has been at least 30% of the conversion price in effect on each such trading day, or the outstanding balance of convertible bonds is lower than \$100,000 (10% of the total amount originally issued), the Company may redeem all the bonds in cash, at par value, within five business days after the base date of reclamation of the bonds.

- 4) Terms of conversion
 - a) The debtors may opt to have its bonds converted into the Company's ordinary share at par value and at the conversion price at the time the conversion is requested, from the day following the expiration of three month after the issuance of the convertible corporate debt, up to the expiry date, except for the following:
 - i) The period during which the transfer of ordinary shares of the Company is suspended in accordance with the law and the period commencing from the date on which the transfer of bonus share issued ceases.
 - ii) The date on which the transfer of cash dividends ceases or 15 business days before the date on which the transfer of shares of cash capital increase ceases, until the date of record for the distribution of the rights or benefits.
 - iii) The period starting from the date of record of the capital decrease and ends on the date prior to the trading of the reissuance shares after the capital decrease, where the conversion request is denied from the conversion cease date of changing par value of shares until the day before trading of reissuance shares with new shares.
 - iv) The conversion cease date of the changing of par value of shares mentioned in the previous paragraph which refers to one business day before the change of registration is applied to the Ministry of Economic Affairs.
 - b) Conversion price: NT\$200 per share. However, due to the previous changes in the conversion prices at the dates of distribution of cash dividends, the conversion price beginning on July 7, 2025 had been adjusted from NT\$192.5 to NT\$184.1.

Since the maturity date of the aforementioned convertible bonds is June 29, 2026, the convertible bonds were reclassified as current liabilities as of June 30, 2025.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

- (ii) The information on the Company's convertible options separated from its recognized liabilities was as follows:

The compounded interest present values of the convertible bond's face value	\$ 950,900
The embedded derivative asset at issuance — call option	(100)
The equity components at issuance	<u>59,200</u>
The total amount of the convertible bonds at issuance	<u><u>\$ 1,010,000</u></u>

- (iii) The above components of equity were recorded under capital surplus - conversion rights.

The second unsecured convertible bond issuance costs were allocated to capital surplus - conversion rights at the total amount of \$174 in accordance with IFRSs.

- (iv) For the year ended December 31, 2024, the bondholders exercised their conversion rights for convertible bonds with a face value of \$450,900, which were converted into ordinary shares and bond conversion entitlement certificates of \$18,546 and \$4,851, respectively, offsetting the discount on the bonds payable of \$12,641. The capital surplus generated was recognized at \$414,856 (including the write-down on capital surplus - stock options of \$26,615 and the cash refund from fractional shares of \$6).
- (v) For the year ended December 31, 2025, the bondholders exercised their conversion rights for convertible bonds with a face value of \$244,700, which were converted into ordinary shares and bond conversion entitlement certificates of \$7,885 and \$5,268, respectively, offsetting the discount on the bonds payable of \$2,664. The capital surplus generated was recognized at \$228,874 (including the write-down on capital surplus - stock options of \$14,444 and the cash refund from fractional shares of \$9). As of December 31, 2025, there was still a remaining face value of \$304,400 of corporate bonds that has not been converted. In addition to the above, the Company did not issue, repurchase, or repay any outstanding corporate bonds for the year ended December 31, 2025.

- (n) Lease liabilities

The lease liabilities of the Company were as follows:

	December 31, 2025	December 31, 2024
Current	<u>\$ 39,698</u>	<u>37,552</u>
Non-current	<u>\$ 67,060</u>	<u>50,783</u>

For the maturity analysis, please refer to note 6(v).

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

The amounts recognized in profit or loss were as follows:

	<u>2025</u>	<u>2024</u>
Interest on lease liabilities	\$ <u>1,728</u>	<u>1,922</u>
Variable lease payments not included in the measurement of lease liabilities	\$ <u>7,906</u>	<u>3,767</u>
Expenses relating to short-term leases	\$ <u>19,010</u>	<u>3,449</u>
Expense relating to leases of low-value assets, excluding short-term leases of low-value assets	\$ <u>8,436</u>	<u>7,528</u>

The amounts recognized in the statements of cash flows for the Company were as follows:

	<u>2025</u>	<u>2024</u>
Total cash outflow for leases	\$ <u>89,137</u>	<u>83,399</u>

(i) Real estate leases

As of December 31, 2025 and 2024, the Company leases land and buildings for its office space, erecting solar power generation equipment and warehouse. The leases of office space and warehouse typically run for a period of 1 to 20 years, and of buildings for erecting solar power generation equipment for 20 years. Some leases include an option to renew the lease for an additional period of the same duration after the end of the contract term.

Some leases require the Company to make payments that relate to the property taxes levied on the lessor and insurance payments made by the lessor; these amounts are generally determined annually.

(ii) Other leases

The Company leases vehicles, with lease terms of 1 to 5 years. In some cases, the Company has options to purchase the assets at the end of the contract term; in other cases, it guarantees the residual value of the leased assets at the end of the contract term.

The Company also leases IT equipment with contract terms of 1 to 3 years. These leases are short-term or leases of low-value items. The Company has elected not to recognize right-of-use assets and lease liabilities for these leases.

(o) Employee benefits

(i) Defined benefit plans

Reconciliation of the defined benefit obligations at present value and of plan assets at present value were as follows:

	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Present value of defined benefit obligations	\$ (278,688)	(268,580)
Fair value of plan assets	<u>139,567</u>	<u>130,801</u>
Net defined benefit liabilities	\$ <u>(139,121)</u>	<u>(137,779)</u>

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

The Company makes defined benefit plan contributions to the pension fund account at the Bank of Taiwan that provides pensions for employees upon retirement. The plans covered by the Labor Standards Law entitle a retired employee to receive retirement benefits based on years of service and average monthly salary for the six months prior to retirement.

1) Composition of plan assets

The Company allocates pension funds in accordance with the Regulations for Revenues, Expenditures, Safeguard and Utilization of the Labor Retirement Fund, and such funds are managed by the Bureau of Labor Funds Ministry of Labor. With regard to the utilization of the funds, minimum earnings shall be no less than the earnings attainable from two-year time deposits with interest rates offered by local banks.

The Company's Bank of Taiwan labor pension reserve account balance amounted to \$139,567 as of reporting date. For information on the utilization of the labor pension fund assets, including the asset allocation and yield of the fund, please refer to the website of the Bureau of Labor Funds Ministry of Labor.

2) Movements in present value of defined benefit obligations

The movements in present value of defined benefit obligations for the Company were as follows:

	2025	2024
Defined benefit obligation at January 1	\$ (268,580)	(249,275)
Current service costs and interest costs	(5,355)	(4,353)
Remeasurements of net defined benefit liabilities	(11,305)	(14,952)
Benefits paid by plan assets	6,552	-
Defined benefit obligations at December 31	<u>\$ (278,688)</u>	<u>(268,580)</u>

3) Movements of defined benefit plan assets

The movements in the present value of the defined benefit plan assets for the Company were as follows:

	2025	2024
Fair value of plan assets at January 1	\$ 130,801	116,657
Contributions paid by the employer	2,400	2,400
Expected return on plan assets	2,058	1,473
Remeasurements of net defined benefit liabilities	9,006	10,271
Benefits paid by plan assets	(4,698)	-
Fair value of plan assets at December 31	<u>\$ 139,567</u>	<u>130,801</u>
Actual return on plan assets	<u>\$ 11,064</u>	<u>11,745</u>

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

4) Expenses recognized in profit or loss

The expenses recognized in profit or loss for the years ended December 31, 2025 and 2024 were as follows:

	<u>2025</u>	<u>2024</u>
Service cost	\$ 565	745
Net interest of net liabilities for defined benefit obligations	<u>2,732</u>	<u>2,135</u>
	<u>\$ 3,297</u>	<u>2,880</u>
Selling expenses	-	-
Administrative expenses	<u>\$ 3,297</u>	<u>2,880</u>
	<u>\$ 3,297</u>	<u>2,880</u>

5) Remeasurement of net defined benefit liability recognized in other comprehensive income:

The Company's re-measurements of the net defined benefit liability recognized in other comprehensive income for the years ended December 31, 2025 and 2024, were as follows:

	<u>2025</u>	<u>2024</u>
Accumulated amount at January 1	\$ 60,472	55,791
Recognized during the period	<u>2,299</u>	<u>4,681</u>
Accumulated amount at December 31	<u>\$ 62,771</u>	<u>60,472</u>

6) Actuarial assumptions

The following are the Company's principal actuarial assumptions at the reporting date:

	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Discount rate	1.750 %	2.000 %
Future salary increases rate	4.00 %	4.00 %

The expected allocation payment to be made by the Company to the defined benefit plans for the one-year period after the reporting date is \$2,400.

The weighted-average lifetime of the defined benefit plan is 11.28 years.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

7) Sensitivity analysis

If the main actuarial assumptions had changed, the impact on the present value of the defined benefit obligation shall be as follows:

	Effects to the defined benefit obligation	
	Increased 0.25%	Decreased 0.25%
December 31, 2025		
Discount rate	\$ (3,902)	4,012
Future salary increasing rate	3,819	(3,735)
December 31, 2024		
Discount rate	(4,149)	4,272
Future salary increasing rate	4,086	(3,991)

Reasonably possible changes at the reporting date to one of the relevant actuarial assumptions, holding other assumptions constant, would have affected the defined benefit obligation by the amounts shown above. The method used in the sensitivity analysis is consistent with the calculation of pension liabilities in the balance sheets.

There is no change in the method and assumptions used in the preparation of sensitivity analysis for this period and previous period.

(ii) Defined contribution plans

The Company allocates 6% of each employee's monthly wages to the labor pension personal account at the Bureau of the Labor Insurance in accordance with the provisions of the Labor Pension Act. Under this defined contribution plan, the Company allocates a fixed amount to the Bureau of the Labor Insurance without additional legal or constructive obligations.

The Company recognized the pension costs under the defined contribution method amounting to \$31,860 and \$30,470 for the years ended December 31, 2025 and 2024, respectively. Payment was made to the Bureau of Labor Insurance.

(p) Income taxes

(i) Income tax expenses

1) The components of income tax for the years ended December 31, 2025 and 2024 were as follows:

	2025	2024
Current tax expense		
Current period	\$ 733,126	464,058
Surtax on unappropriated earnings	51,898	41,348
	785,024	505,406
Deferred tax expense		
Origination and reversal of temporary differences	(11,311)	78,683
Income tax expense	\$ 773,713	584,089

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

- 2) The amounts of income tax recognized in other comprehensive income for 2025 and 2024 were as follows:

	2025	2024
Items that may not be reclassified subsequently to profit or loss:		
Remeasurements from defined benefit plans	\$ (460)	(936)
Items that may be reclassified subsequently to profit or loss:		
Exchange differences on translation of foreign financial statements	(6,992)	34,041
	\$ (7,452)	33,105

- 3) Reconciliations of income tax and profit before tax for 2025 and 2024 were as follows:

	2025	2024
Profit before tax	\$ 4,954,160	4,240,024
Income tax calculated based on local tax rate of the Company	990,832	848,005
Tax exemption income and domestic investment income, net	(225,074)	(228,947)
Effect of foreign dividend income and its applicable exchange rate difference	(14,269)	19,492
Estimated difference adjustment and others	754	(2,033)
Surtax on unappropriated earnings	51,898	41,348
Surtax on unappropriated earnings practical adjustment	(30,428)	(93,776)
	\$ 773,713	584,089

(ii) Deferred tax assets and liabilities

- 1) Unrecognized deferred tax assets and liabilities

The Company's deferred tax assets have not been recognized in respect of the following items:

	December 31, 2025	December 31, 2024
Tax effect of deductible temporary differences	\$ 5,153	5,153

Deferred tax assets were not recognized because the deductible temporary differences may not be realized in the future.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

2) Recognized deferred tax assets and liabilities

Changes in the amount of deferred tax assets and liabilities for 2025 and 2024 were as follows:

	<u>Defined benefit plan</u>	<u>Exchange differences on translation of foreign financial statements</u>	<u>Others</u>	<u>Total</u>
Deferred tax assets:				
Balance at January 1, 2025	\$ 28,423	-	12,010	40,433
Recognized in profit or loss	179	-	4,609	4,788
Recognized in other comprehensive income	<u>460</u>	<u>-</u>	<u>-</u>	<u>460</u>
Balance at December 31, 2025	<u>\$ 29,062</u>	<u>-</u>	<u>16,619</u>	<u>45,681</u>
Balance at January 1, 2024	\$ 27,391	21,510	15,024	63,925
Recognized in profit or loss	96	-	(3,014)	(2,918)
Recognized in other comprehensive income	<u>936</u>	<u>(21,510)</u>	<u>-</u>	<u>(20,574)</u>
Balance at December 31, 2024	<u>\$ 28,423</u>	<u>-</u>	<u>12,010</u>	<u>40,433</u>

	<u>Foreign investment income under equity method</u>	<u>Exchange differences on translation of foreign financial statements</u>	<u>Others</u>	<u>Total</u>
Deferred tax liabilities:				
Balance at January 1, 2025	\$ 649,912	12,531	15,903	678,346
Recognized in profit or loss	(26,493)	-	19,970	(6,523)
Recognized in other comprehensive income	<u>-</u>	<u>(6,992)</u>	<u>-</u>	<u>(6,992)</u>
Balance at December 31, 2025	<u>\$ 623,419</u>	<u>5,539</u>	<u>35,873</u>	<u>664,831</u>
Balance at January 1, 2024	\$ 578,475	-	11,575	590,050
Recognized in profit or loss	71,437	-	4,328	75,765
Recognized in other comprehensive income	<u>-</u>	<u>12,531</u>	<u>-</u>	<u>12,531</u>
Balance at December 31, 2024	<u>\$ 649,912</u>	<u>12,531</u>	<u>15,903</u>	<u>678,346</u>

(iii) The ROC tax authorities have examined the income tax returns of the Company through 2022.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

(q) Capital and other equities

(i) Common stock

As of December 31, 2025 and 2024, the total values of authorized ordinary shares were amounted to \$2,500,000 and \$2,200,000, respectively. (including \$100,000 for the issuance of employee stock options). The number of authorized ordinary shares were 250,000 and 220,000 thousand shares, respectively, with par value of New Taiwan Dollars \$10 per share. As of that date, \$192,355 and \$191,040 thousand of ordinary shares were issued, respectively. All issued shares were paid up upon issuance.

(ii) Reconciliations of shares outstanding for 2025 and 2024 are as follows (in thousands of shares):

	Ordinary Shares	
	2025	2024
Balance on January 1	191,040	188,700
Conversion of convertible bonds	1,315	2,340
Balance on December 31	192,355	191,040

The Company issued \$2,340 thousand new shares to convertible bond holders who exercised their conversion rights at face value, with a total amount of \$23,397 for the year ended December 31, 2024. As of December 31, 2025, all relevant statutory registration procedures have been completed.

The Company issued \$1,315 thousand new shares to convertible bond holders who exercised their conversion rights at face value, with a total amount of \$13,153 for the year ended December 31, 2025. As of December 31, 2025, the legal registration procedures of \$1,012 thousand shares have not been completed, these shares were recognized as certificate of entitlement to new shares from convertible bond.

(iii) Capital surplus

The balances of capital surplus were as follows:

	December 31, 2025	December 31, 2024
Capital premium	\$ 3,122,491	2,879,173
Convertible bonds-conversion options	17,967	32,411
Changes in the equity ownership of the subsidiaries	1,965	1,965
Stock option – fair value differences of associates and joint ventures accounted under equity method	2,270	2,270
Others	422	422
	\$ 3,145,115	2,916,241

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

According to the R.O.C. Company Act, capital surplus can only be used to offset a deficit, and only the realized capital surplus can be used to increase the common stock or be distributed as cash dividends. The aforementioned realized capital surplus includes capital surplus resulting from premium on issuance of capital stock and earnings from donated assets received. According to the Regulations Governing the Offering and Issuance of Securities by Securities Issuers, capital increases by transferring capital surplus in excess of par value should not exceed 10% of the total common stock outstanding.

On February 29, 2024, the Company's Board of Directors resolved to distribute the cash dividends of \$188,700 (New Taiwan dollars \$1 per share) from capital surplus.

(iv) Retained earnings

According to the Company's articles of incorporation, 10% of annual net earnings (net of incomes taxes), after deducting accumulated deficits, must be set aside as legal reserve. In addition, a special reserve shall be set aside in accordance with applicable laws and regulations. The remaining profit, together with the beginning balance of undistributed retained earnings, can be distributed according to the distribution plan proposed by the Board of directors and submitted during the stockholders' meeting for approval. The distribution of earnings or legal reserve and capital surplus, by way of cash, shall be decided during the board meeting, approved by more than half of the directors, with two thirds of directors in attendance; thereafter, to be reported in the shareholders' meeting of the Company.

According to the Company's dividend policy, the type of dividends should be determined after considering the remaining portion of retained earnings, the business environment, etc. The dividends could be paid whether by cash or stock. No less than 10% of total stockholders' dividends may be distributed in the form of cash dividends. Any remaining profit didn't distributed in the form of cash dividends could be distributed in the form of stock dividends according to the Company's articles proposed by the Board of directors and submitted to the stockholders' meeting for approval.

1) Legal reserve

When a company incurs no loss, it may, pursuant to a resolution by the shareholders' meeting, distribute its legal reserve by issuing new shares or by distributing cash. Only the portion of the legal reserve which exceeds 25% of capital may be distributed.

2) Special reserve

A portion of current-period earnings and undistributed prior-period earnings shall be reclassified as a special earnings reserve during earnings distribution. The amount to be reclassified should equal the current-period total net reduction of other shareholders' equity. Similarly, while distributing the surplus, a portion of undistributed prior period earnings shall be reclassified as a special earnings reserve (and does not qualify for earnings distribution) to account for cumulative changes to other shareholders' equity pertaining to prior periods. Amounts of subsequent reversals pertaining to the net reduction of other shareholders' equity shall qualify for additional distributions.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

3) Earnings distribution

The amount of cash dividends of appropriations of earnings for 2024 and 2023 had been approved in the Board meetings held on February 27, 2025 and February 29, 2024, respectively. The amount of other appropriation items of earnings for 2024 and 2023 had been approved in the regular shareholders' meetings held on May 29, 2025 and May 30, 2024, respectively. These earnings were appropriated as follows:

	<u>2024</u>		<u>2023</u>	
	<u>Amount per share NT (Dollars)</u>	<u>Total amount</u>	<u>Amount per share NT (Dollars)</u>	<u>Total amount</u>
Dividends distributed to common shareholder:				
Cash dividends	\$ 11.99	<u><u>2,293,351</u></u>	9.0	<u><u>1,698,296</u></u>

On March 10, 2026, the Company's Board of Directors resolved to appropriate the 2025 earnings. These earnings were appropriated as follows:

	<u>2025</u>	
	<u>Amount per share NT (Dollars)</u>	<u>Total amount</u>
Dividends distributed to common shareholder:		
Cash dividends	\$ 13.5	<u><u>2,603,218</u></u>

The information earning distribution can be accessed from the Market Observation Post System after the shareholders' meeting.

4) Other equity

	<u>Exchange differences on translation of foreign financial statements</u>	<u>Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income</u>	<u>Total</u>
Balance at January 1, 2025	\$ 46,882	1,137,221	1,184,103
Exchange differences on foreign operations:			
Subsidiary	(27,968)	-	(27,968)
Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income:			
The Company	-	120,415	120,415
Subsidiary	-	8,800	8,800
Balance at December 31, 2025	<u><u>\$ 18,914</u></u>	<u><u>1,266,436</u></u>	<u><u>1,285,350</u></u>

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

	Exchange differences on translation of foreign financial statements	Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income	Total
Balance at January 1, 2024	\$ (90,453)	866,377	775,924
Exchange differences on foreign operations:			
Subsidiaries	137,335	-	137,335
Unrealized gains (losses) from financial assets measured at fair value through other comprehensive income:			
The Company	-	338,188	338,188
Subsidiaries	-	(18,239)	(18,239)
Disposal of investments in equity instruments designated at fair value through other comprehensive income	-	(49,105)	(49,105)
Balance at December 31, 2024	\$ 46,882	1,137,221	1,184,103

(r) Earnings per share

The calculation of basic and diluted earnings per share for the years 2025 and 2024 are as follows:

	2025	2024
Basic earnings per share:		
Profit attributable to ordinary shareholders of the Company	\$ <u>4,180,447</u>	<u>3,655,935</u>
Weighted-average number of outstanding ordinary shares (thousands)	<u>191,644</u>	<u>189,549</u>
Basic earnings per share (dollars)	\$ <u>21.81</u>	<u>19.29</u>
Diluted earnings per share:		
Profit attributable to ordinary shareholders of the Company	\$ 4,180,447	3,655,935
The after-tax impact of interest on convertible bonds and other income or losses	<u>7,672</u>	<u>13,633</u>
Profit attributable to ordinary shareholders of the Company (after adjustment of potential diluted ordinary shares)	\$ <u>4,188,119</u>	<u>3,669,568</u>
Weighted-average number of outstanding ordinary shares (thousands)	191,644	189,549
Effect of diluted potential ordinary share (thousands)		
Effect of conversion of convertible bonds	2,364	4,236
Effect of employee share bonuses	<u>1,719</u>	<u>1,600</u>
Weighted-average number of ordinary shares (after adjustment of potential diluted ordinary shares)	<u>195,727</u>	<u>195,385</u>
Diluted earnings per share (dollars)	\$ <u>21.40</u>	<u>18.78</u>

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

(s) Revenue from contracts with customers

(i) Details of revenue

	<u>2025</u>	<u>2024</u>
Primary geographical markets:		
Taiwan	\$ 26,532,219	21,573,374
China	14,055,952	9,192,518
Others	<u>225,616</u>	<u>489,409</u>
	<u>\$ 40,813,787</u>	<u>31,255,301</u>
Major products / services:		
Semiconductor and optoelectronic industries	\$ 40,728,336	31,172,077
Others	<u>85,451</u>	<u>83,224</u>
	<u>\$ 40,813,787</u>	<u>31,255,301</u>

(ii) Contract balance

	<u>December 31, 2025</u>	<u>December 31, 2024</u>	<u>January 1, 2024</u>
Notes and accounts receivable (including related parties)	\$ 6,294,462	4,232,237	3,163,594
Less: allowance for impairment	<u>10,112</u>	<u>5,495</u>	<u>4,399</u>
Total	<u>\$ 6,284,350</u>	<u>4,226,742</u>	<u>3,159,195</u>
Contract liabilities – unearned revenue	<u>\$ 295,551</u>	<u>240,555</u>	<u>165,230</u>

For details on accounts receivable and allowance for impairment, please refer to note 6(d).

The amounts of revenue recognized for the years ended December 31, 2025 and 2024 that were included in contract liability balance at the beginning of the period were \$212,864 and \$130,631, respectively.

The major change in the balance of contract assets and contract liabilities is the difference between the time frame in the performance obligation to be satisfied and the payment to be received. There were no significant changes for the years ended December 31, 2025 and 2024.

(t) Remuneration to employees, directors

On May 29, 2025, the Company resolved at the shareholders' meeting to amend its Articles of Incorporation. According to the amended Company Article of Incorporation, if the Company incurs profit for the year, the profit shall first be used to offset against any accumulated deficits. Thereafter, a maximum of 3% of the remainder shall be allocated as directors' remuneration, and not less than 4% (in shares or in cash) as employee remuneration, including a minimum of 8% to those base-level employees. The distribution shall also include those employees of the Company's subsidiaries who meet certain requirements.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

According to the Company's articles of incorporation, earning shall first be offset against any deficit, then, a minimum of 4% net profit before tax will be distributed as employee remuneration and a maximum of 3% will be allocated as directors' remuneration. Employees who are entitled to receive the abovementioned employee remuneration, in share or cash, include those of the subsidiaries of the Company who meet certain specific requirements.

For the years ended December 31, 2025 and 2024, the Company estimated its employees' remuneration amounting to \$440,370 and \$376,891, respectively, and the directors' remuneration amounting to \$110,092 and \$94,223, respectively. The estimated amounts mentioned above are calculated based on the net profit before tax, excluding the remuneration to employees and directors of each period, multiplied by the percentage of remuneration to employees and directors as specified in the Company's articles. These remunerations were expensed under operating expenses during 2025 and 2024. If there are any subsequent adjustments to the actual remuneration amounts after the annual shareholder' meeting, the adjustment will be regarded as changes in accounting estimates and will be reflected in profit or loss in the following year. Shares distributed to employees as employees' remuneration are calculated based on the closing price of the Company's ordinary shares on the day before the approval by the Board of Directors. Related information would be available at the Market Observation Post System website.

(u) Non-operating income and expenses

(i) Other income

The details of other income for the years ended December 31, 2025 and 2024 were as follows:

	2025	2024
Rental income	\$ 15,342	13,035
Dividend income	95,555	74,299
Government grants	46	7,624
Others	16,429	23,571
	<u>\$ 127,372</u>	<u>118,529</u>

(ii) Other gains and losses

The details of other gains and losses for the years ended December 31, 2025 and 2024 were as follows:

	2025	2024
Foreign currency exchange gains, net	\$ (35,015)	12,150
Gains on financial assets and liabilities at fair value through profit or loss, net	423,372	99,377
Losses on disposal of property, plant and equipment, net	(2,529)	(2,647)
Others	(626)	(3,533)
	<u>\$ 385,202</u>	<u>105,347</u>

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

(v) Financial instruments

(i) Credit risk

1) Credit risk – exposure to credit risk

The carrying amount of financial assets and contract assets represents the maximum amount exposed to credit risk.

2) Concentration to credit risk

The customers of the Company are diverse instead of concentrating on specific customers; therefore, the Company has not suffered any significant credit loss. The Company periodically evaluates the financial positions of these customers to reduce the credit risk of accounts receivables.

3) Receivables and debt securities

For credit risk exposure of note and account receivables, please refer to note 6(d).

These financial assets are considered to have low risk, and thus, the impairment provision recognized during the period was limited to 12 months expected losses. The loss allowance provisions were determined as follows:

	<u>2025</u>	<u>2024</u>
Balance at January 1	\$ 14,300	14,300
Impairment loss	<u>-</u>	<u>-</u>
Balance at December 31	<u>\$ 14,300</u>	<u>14,300</u>

(ii) Liquidity risk

The following were the contractual maturities of financial liabilities, including estimated interest payments.

	<u>Carrying Amount</u>	<u>Contractual cash flows</u>	<u>Within a year</u>	<u>1 ~ 2 years</u>	<u>Over 2 years</u>
December 31, 2025					
Non-derivative financial liabilities					
Long-term bank loans	\$ 1,900,000	(2,178,860)	(38,600)	(102,734)	(2,037,526)
Notes and accounts payable (including related parties)	6,521,871	(6,521,871)	(6,521,871)	-	-
Accrued expenses and other payables	1,231,352	(1,231,352)	(1,231,352)	-	-
Lease liabilities (including current and non-current)	106,758	(110,651)	(40,983)	(27,259)	(42,409)
Bonds payable (including current and non-current)	<u>298,078</u>	<u>(304,400)</u>	<u>(304,400)</u>	<u>-</u>	<u>-</u>
	<u>\$ 10,058,059</u>	<u>(10,347,134)</u>	<u>(8,137,206)</u>	<u>(129,993)</u>	<u>(2,079,935)</u>

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

	<u>Carrying Amount</u>	<u>Contractual cash flows</u>	<u>Within a year</u>	<u>1 ~ 2 years</u>	<u>Over 2 years</u>
December 31, 2024					
Non-derivative financial liabilities					
Short-term bank loans	\$ 460,000	(460,521)	(460,521)	-	-
Long-term bank loans	1,580,000	(1,895,425)	(32,776)	(32,776)	(1,829,873)
Notes and accounts payable (including related parties)	4,260,773	(4,260,773)	(4,260,773)	-	-
Accrued expenses and other payables	998,872	(998,872)	(998,872)	-	-
Lease liabilities (including current and non-current)	88,335	(92,169)	(38,741)	(20,273)	(33,155)
Bonds payable	<u>532,746</u>	<u>(549,100)</u>	<u>-</u>	<u>(549,100)</u>	<u>-</u>
	<u>\$ 7,920,726</u>	<u>(8,256,860)</u>	<u>(5,791,683)</u>	<u>(602,149)</u>	<u>(1,863,028)</u>

The Company does not expect the cash flows included in the maturity analysis to occur significantly earlier or at significantly different amount.

(iii) Currency risk

1) Exposure to foreign currency risk

The Company's significant financial assets and liabilities exposed to foreign currency risk were as follows:

	<u>December 31, 2025</u>			<u>December 31, 2024</u>		
	<u>Foreign currency</u>	<u>Exchange rate</u>	<u>NTD</u>	<u>Foreign currency</u>	<u>Exchange rate</u>	<u>NTD</u>
Financial assets						
Monetary items						
USD	\$ 133,569	31.43	4,198,074	93,051	32.785	3,050,677
JPY	11,338,681	0.2008	2,276,807	6,709,981	0.2099	1,408,425
Financial liabilities						
Monetary items						
USD	119,746	31.43	3,763,617	82,266	32.785	2,697,091
JPY	10,836,736	0.2008	2,176,017	6,001,364	0.2099	1,259,686

2) Sensitivity analysis

The Company's exposure to foreign currency risk arises from the translation of the foreign currency exchange gains and losses on cash and cash equivalents, account and other receivables, loans and borrowings, and account and other payables that are denominated in foreign currency. A appreciation (depreciation) of 5% of the each major foreign currency against Company's functional currency as of December 31, 2025 and 2024 would have influenced the net profit before tax as follows. The analysis is performed on the same basis for both periods.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

	<u>December 31, 2025</u>	<u>December 31, 2024</u>
USD (against the NTD)		
Appreciation 5%	\$ 21,723	17,679
Depreciation 5%	(21,723)	(17,679)
JPY (against the NTD)		
Appreciation 5%	5,040	7,437
Depreciation 5%	(5,040)	(7,437)

3) Foreign exchange gain and loss on monetary items

Since the Company has many kinds of functional currency, the information on foreign exchange gain (loss) on monetary items is disclosed by total amount. Foreign exchange gain (loss) (including realized and unrealized portions) were as follows:

	<u>2025</u>	<u>2024</u>
Foreign exchange gains (losses) (including realized and unrealized portions)	<u>\$ (35,015)</u>	<u>12,150</u>

(iv) Interest rate analysis

The details of financial assets and liabilities exposed to interest rate risk were as follows:

	<u>Carrying amount</u>	
	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Variable rate instruments:		
Financial assets	\$ 1,062,023	381,155
Financial liabilities	1,900,000	2,030,000

The following sensitivity analysis is based on the exposure to the interest rate risk of derivative and non-derivative financial instruments on the reporting date. Regarding the assets and liabilities with variable interest rates, the analysis is on the basis of the assumption that the amount of assets and liabilities outstanding at the reporting date were outstanding throughout the year. The rate of change is expressed as the interest rate increase or decrease by 0.25% when reporting to management internally, which also represents management of the Company's assessment on the reasonably possible interval of interest rate change.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

If the interest rate had increased or decreased by 0.25%, the net profit before tax would have decreased or increased by the amounts listed below for the years ended December 31, 2025 and 2024, respectively, which would be mainly resulted from the bank savings, time deposits with variable interest rates and borrowings.

	December 31, 2025	December 31, 2024
Interest rate increased by 0.25%	\$ (2,095)	(4,122)
Interest rate decreased by 0.25%	2,095	4,122

(v) Fair value of financial instruments

1) Evaluation process and fair value hierarchy

The disclosures of financial assets and liabilities are measured using the fair value method based on the Company's accounting policy. The Company's management is responsible in performing independent test on fair value by using independent source of information to obtain the fair value which is close to the market status. The management also confirms the independence, reliability and matching of the information source. In addition, it regularly tests the valuation model, updates the input and other information, as well as makes necessary adjustment to ensure the output of valuation is reasonable.

The Company uses observable market data to evaluate its assets and liabilities when it is possible. The different inputs of levels of fair value hierarchy in determination the fair value are as follows:

Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3: inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

2) Fair value hierarchy

The fair value of financial assets and liabilities at fair value through profit or loss and financial assets fair value through other comprehensive income is measured on a recurring basis. The carrying amount and fair value of the Company's financial assets and liabilities, including the information on fair value hierarchy were as follows; however, except as described in the following paragraphs, for financial instruments not measured at fair value whose carrying amount is reasonably close to the fair value, and lease liabilities disclosure of fair value information is not required:

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

	December 31, 2025				
	Book value	Fair value			Total
		Level 1	Level 2	Level 3	
Financial assets at fair value through profit or loss					
Convertible bonds - embedded derivatives	\$ 27	-	-	27	27
Non derivative financial assets mandatorily measured at fair value through profit or loss-domestic listed stocks	98,774	98,774	-	-	98,774
Non derivative financial assets mandatorily measured at fair value through profit or loss-foreign listed stocks	175,964	175,964	-	-	175,964
Non derivative financial assets mandatorily measured at fair value through profit or loss-unlisted stocks and limited partnership	526,455	336,855	-	189,600	526,455
Non derivative financial assets mandatorily measured at fair value through profit or loss-foreign unlisted funds	<u>28,471</u>	-	-	28,471	28,471
Subtotal	<u>829,691</u>				
Financial assets at fair value through other comprehensive income	<u>1,606,165</u>	169,575	-	1,436,590	1,606,165
Financial assets measured at amortized cost					
Cash and cash equivalents	1,354,047	-	-	-	-
Notes and accounts receivable (including related parties)	6,284,350	-	-	-	-
Other current financial assets	44,101	-	-	-	-
Other non-current assets (refundable deposits and pledged asset-time deposits)	<u>115,863</u>	-	-	-	-
Subtotal	<u>7,798,361</u>				
Total	<u>\$ 10,234,217</u>				
Financial liabilities measured at amortized cost					
Long-term bank loans	1,900,000	-	-	-	-
Notes and accounts payable (including related parties)	6,521,871	-	-	-	-
Accrued expenses and other payables	1,231,352	-	-	-	-
Lease liabilities (including current and non-current)	106,758	-	-	-	-
Bonds payable	<u>298,078</u>	-	-	-	-
Total	<u>\$ 10,058,059</u>				

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

	December 31, 2024				
	Book value	Fair value			Total
		Level 1	Level 2	Level 3	
Financial assets fair value through profit or loss					
Convertible bonds-embedded derivatives	\$ 410	-	-	410	410
Non-derivative financial assets mandatorily measured at fair value through profit or loss - domestic listed stocks	133,260	133,260	-	-	133,260
Non derivative financial assets mandatorily measured at fair value through profit or loss-foreign listed stocks	72,406	72,406	-	-	72,406
Non derivative financial assets mandatorily measured at fair value through profit or loss-unlisted stocks and limited partnership	257,979	55,080	-	202,899	257,979
Non derivative financial assets mandatorily measured at fair value through profit or loss-foreign unlisted funds	<u>26,580</u>	-	-	26,580	26,580
Subtotal	<u>490,635</u>				
Financial assets at fair value through other comprehensive income	<u>1,485,750</u>	159,885	-	1,325,865	1,485,750
Financial assets measured at amortized cost					
Cash and cash equivalents	656,951	-	-	-	-
Notes and accounts receivable (including related parties)	4,226,742	-	-	-	-
Other current financial assets	12,530	-	-	-	-
Other non-current assets (refundable deposits and pledged assets-time deposits)	<u>202,283</u>	-	-	-	-
Subtotal	<u>5,098,506</u>				
Total	<u>\$ 7,074,891</u>				
Financial liabilities at amortized cost					
Short-term bank loans	\$ 460,000	-	-	-	-
Long-term bank loans	1,580,000	-	-	-	-
Notes and accounts payable (including related parties)	4,260,773	-	-	-	-
Accrued expenses and other payables	998,872	-	-	-	-
Lease liabilities (including current and non-current)	88,335	-	-	-	-
Bonds payable	<u>532,746</u>	-	-	-	-
Total	<u>\$ 7,920,726</u>				

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

3) Valuation techniques for financial instruments not measured at fair value

The Company valuation techniques and assumptions used for financial instrument not measured at fair value are as follows:

If there is quoted price generated by transactions, the recent transaction price and quoted price data is used as the basis for fair value measurement. However, if no quoted prices are available, the discounted cash flows are used to estimate fair values.

4) Valuation techniques for financial instruments measured at fair value – Non-derivative financial instruments

a) Non-derivative financial instruments

Financial instruments traded in active markets are based on quoted market prices. The quoted price of a financial instrument obtained from main exchanges and the government bond with high trading volume can be used as a basis to determine the fair value of the listed companies' equity instrument and the debt instrument of the quoted price in an active market.

b) Derivative financial instruments

Measurement on the fair value of derivative instruments is based on the valuation techniques generally accepted by market participants such as the binomial tree pricing model.

5) Transfer between levels

The Company's equity holdings of Beiley Biofund Inc. shares were classified as financial assets measured at fair value through profit or loss; the fair value of these financial assets as of December 31, 2024, was \$79,982. As of December 31, 2024, the investment was classified as Level 3 because the company's shares had no quoted market prices and their fair value was measured using significant unobservable inputs. Beiley Biofund Inc. began to trade as an emerging stock in December 2025, resulting in active market quotes; consequently, its fair value measurement was reclassified from Level 3 to Level 1.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

6) Reconciliation of level 3 fair value

	<u>Financial assets at fair value through profit or loss</u>		<u>Financial assets at fair value through other comprehensive income</u>	<u>Total</u>
	<u>Derivative financial assets- convertible bonds</u>	<u>Debt investment without quoted price</u>	<u>Equity investment without quoted price</u>	
Balance at January 1, 2025	\$ 410	229,479	1,325,865	1,555,754
Total gains and losses recognized:				
In profit (loss)	(383)	37,180	-	36,797
In other comprehensive income	-	-	110,725	110,725
Purchased	-	33,333	-	33,333
Proceeds of capital reduction of investment	-	(1,939)	-	(1,939)
Reclassify from Level 3	-	(79,982)	-	(79,982)
Balance at December 31, 2025	<u>\$ 27</u>	<u>218,071</u>	<u>1,436,590</u>	<u>1,654,688</u>
Balance at January 1, 2024	\$ -	226,329	1,124,917	1,351,246
Total gains and losses recognized:				
In profit (loss)	410	5,082	-	5,492
In other comprehensive income	-	-	200,948	200,948
Purchased	-	15,000	-	15,000
Proceeds of capital reduction of investment	-	(16,932)	-	(16,932)
Balance at December 31, 2024	<u>\$ 410</u>	<u>229,479</u>	<u>1,325,865</u>	<u>1,555,754</u>

The above total gains or losses are presented under “Other gains and losses” and “Financial assets at fair value through other comprehensive income – unrealized gains (losses) from valuation.” Details of the related assets still held as of December 31, 2025 and 2024, are as follows:

	<u>2025</u>	<u>2024</u>
Total gains or losses	\$ 147,522	206,440
Recognized in profit or loss (presented under “Other gains and losses”)	36,797	5,492
Recognized in profit or loss (presented under “Other gains and losses”)	110,725	200,948

7) The quantified information on significant unobservable inputs (level 3) used in fair value measurement

The Company’s financial instruments that use level 3 input to measure fair values include financial assets at fair value through other comprehensive income— equity instruments, financial assets at fair value through profit or loss— convertible bonds redemption rights and financial assets at fair value through profit or loss— equity securities investment.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

Most of fair value measurements of the Company which are categorized as equity investment into level 3 have single significant unobservable inputs, and equity investments without quoted price have several significant unobservable inputs. Significant unobservable inputs of equity investments without quoted price are independent of each other.

The quantified information for significant unobservable inputs was as follows:

<u>Item</u>	<u>Valuation technique</u>	<u>Significant unobservable inputs</u>	<u>Inter relationships between significant unobservable inputs and fair value measurement</u>
Financial assets at fair value through other comprehensive income – equity investment without quoted price	Comparable market approach	Price Book ratio multiples. (10.48~106.7 and 10.64~93.68, respectively, on December 31, 2025 and 2024)	The higher the multiple is, the higher the fair value will be.
		Lack of Marketability discount rate (20% both on December 31, 2025 and 2024)	The higher the lack of marketability discount rate is, the lower the fair value will be.
	Net asset value method	Net asset value method	Inapplicable
Financial assets at fair value through profit or loss – debt investment without quoted price	Net asset value method	Net asset value method	Inapplicable
Financial assets at fair value through profit or loss – convertible bonds redemption right	Binomial convertible bonds pricing models	Volatility (31.33% and 27.24%, respectively, on December 31, 2025 and 2024)	The higher the volatility, the higher the fair value will be.
8) Fair value measurements in Level 3 – sensitivity analysis of reasonably possible alternative assumptions			

For fair value measurements in Level 3, changing one or more of the assumptions to reflect reasonably possible alternative assumptions would have the following effects:

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

	Input	Move up or down	Impacts of fair value change on net income or loss		Impacts of fair value change on other comprehensive income	
			Favorable change	Unfavorable change	Favorable change	Unfavorable change
December 31, 2025						
Financial assets at fair value through other comprehensive income			\$			
Equity investment without quoted price	P/B ratio	5%	\$ <u>-</u>	<u>-</u>	<u>71,886</u>	<u>(71,766)</u>
	Lack of marketability discount	5%	\$ <u>-</u>	<u>-</u>	<u>89,787</u>	<u>(89,787)</u>
December 31, 2024						
Financial assets at fair value through other comprehensive income						
Equity investment without quoted price	P/B ratio	5%	\$ <u>-</u>	<u>-</u>	<u>66,245</u>	<u>(66,245)</u>
	Lack of marketability discount	5%	\$ <u>-</u>	<u>-</u>	<u>82,867</u>	<u>(82,867)</u>

The favorable and unfavorable effects represent the changes in fair value, and fair value is based on a variety of unobservable inputs calculated using a valuation technique. The analysis above only reflects the effects of changes in a single input, and it does not include the interrelationships with another input.

(w) Financial risk management

(i) Briefings

The Company is exposed to the following risks arising from financial instruments:

- 1) Credit risk
- 2) Liquidity risk
- 3) Market risk

The following likewise discusses the Company's objectives, policies and processes for measuring and managing the above mentioned risks. For more disclosures about the quantitative effects of these risks exposures, please refer to the respective notes in the accompanying financial statements.

(ii) Structure of risk management

The Company's finance department provides business services for the overall internal department. It sets the objectives, policies and processes for managing the risk and the methods used to measure the risk arising from both the domestic and international financial market operations.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

The Company minimizes the risk exposure through derivative financial instruments. The Board of Directors regulated the use of derivative and non-derivative financial instruments in accordance with the Company's policy about risks arising from financial instruments such as currency risk, interest rate risk, credit risk, the use of derivative and non-derivative financial instruments and the investments of excess liquidity. The internal auditors of the Company continue with the review of the amount of the risk exposure in accordance with the Company's policies and the risk management policies and procedures. The Company has no transactions in financial instruments (including derivative financial instruments) for the purpose of speculation.

(iii) Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company's receivables from customers and investment securities.

1) Accounts receivable and other receivables

The Company has established a credit policy under which each new customer is analyzed individually for creditworthiness before the Company's standard payment and delivery terms and conditions are offered. The Company's review includes external ratings, when available, and in some cases bank references. Purchase limits are established for each customer, and these limits are reviewed periodically. Customers that fail to meet the Company's benchmark creditworthiness may transact with the Company only on a prepayment basis.

Accounts and other receivables mainly relate to a wide range of customers from different industries and geographic regions. The Company continued to assess the financial condition and credit risk of its customers, by grouping account and other receivables based on their characteristics.

2) Investments

The exposure to credit risk for the bank deposits, fixed income investments, and other financial instruments is measured and monitored by the Company's finance department. The Company only deals with banks, other external parties, corporate organizations, government agencies and financial institutions with good credit rating. The Company does not expect any counterparty above fails to meet its obligations hence there is no significant credit risk arising from these counterparties.

3) Guarantees

Pursuant to the Company's policies, it is only permissible to provide financial guarantees to subsidiaries, companies that the Company has business with, and the investees, based on the percentage of ownership by each shareholder. As of December 31, 2025 and 2024, no guarantees were provided to non-subsidiary. The guarantees provided to subsidiaries please refer to note 13(a).

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

(iv) Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure, as far as possible, that it always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.

Loans and borrowings from the bank form an important source of liquidity for the Company. The Company's unused credit line were amounted to \$6,036,747 and \$6,465,158 as of December 31, 2025 and 2024, respectively.

(v) Market risk

Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and equity prices will affect the Company's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing the return.

The Company buys and sells derivatives, and also incurs financial liabilities, in order to manage market risks.

1) Currency risk

The Company is exposed to currency risk on sales, purchases and borrowings that are denominated in a currency other than the functional currencies of the Company, primarily JPY and USD.

2) Interest rate risk

The Company borrows funds on fixed and variable interest rates, which has a risk exposure to changes in fair value and cash flow.

3) Other price risk

The Company is exposed to equity price risk arising from mutual funds, listed companies' equity investments and emerging stock investments.

(x) Capital management

The policy of Board of Directors is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. Capital consists of ordinary shares, capital surplus, and retained earnings. The Board of Directors monitors the return on capital as well as the level of dividends to ordinary shareholders.

The Company monitors the capital structure by way of periodical review on the liability ratio. The management decided to optimize its capital by using appropriate debt-to-equity ratio. The capital of the Company represents the total equity stated in the balance sheets that is equal to the total assets, minus, total liabilities.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

As of December 31, 2025 and 2024, the liability ratios were as follows:

	<u>December 31, 2025</u>	<u>December 31, 2024</u>
Total liabilities	\$ 11,637,000	9,350,061
Total assets	31,636,753	27,121,283
Liability ratio	37 %	35 %

As of December 31, 2025, there were no changes in the Company's approach to capital management.

(y) Investing and financing activities not affecting current cash flow

The Company's investing and financial activities which did not affect the current cash flow in the years ended December 31, 2025 and 2024, included the acquisition of right-of-use assets through lease. Please refer to notes 6(i) and 6(o) for details.

Reconciliations of liabilities arising from financing activities were as follows:

	<u>January 1, 2025</u>	<u>Cash flow</u>	<u>Non-cash changes</u>			<u>December 31, 2025</u>
			<u>Additions of leases</u>	<u>Cancellation of lease</u>	<u>Other</u>	
Short term borrowings	\$ 460,000	(460,000)	-	-	-	-
Long term borrowings	1,580,000	320,000	-	-	-	1,900,000
Bonds payable	532,746	-	-	-	(234,668)	298,078
Lease liabilities	<u>88,335</u>	<u>(52,057)</u>	<u>73,644</u>	<u>(3,164)</u>	<u>-</u>	<u>106,758</u>
Total liabilities from financing activities	<u>\$ 2,661,081</u>	<u>(192,057)</u>	<u>73,644</u>	<u>(3,164)</u>	<u>(234,668)</u>	<u>2,304,836</u>
			<u>Non-cash changes</u>			
	<u>January 1, 2024</u>	<u>Cash flow</u>	<u>Additions of leases</u>	<u>Cancellation of lease</u>	<u>Other</u>	<u>December 31, 2024</u>
Short term borrowings	\$ 1,255,000	(795,000)	-	-	-	460,000
Long term borrowings	600,000	980,000	-	-	-	1,580,000
Bonds payable	956,809	-	-	-	(424,063)	532,746
Lease liabilities	<u>112,662</u>	<u>(66,733)</u>	<u>43,668</u>	<u>(1,262)</u>	<u>-</u>	<u>88,335</u>
Total liabilities from financing activities	<u>\$ 2,924,471</u>	<u>118,267</u>	<u>43,668</u>	<u>(1,262)</u>	<u>(424,063)</u>	<u>2,661,081</u>

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

(7) Related-party transactions:

(a) Names and relationship with related parties

The followings are entities that have had transactions with related party during the periods covered in the financial statements.

<u>Name of related party</u>	<u>Relationship with the Company</u>
Taiwan E&M System Inc. (Taiwan E&M)	Subsidiary
Topco International Investment Co., Ltd. (Topco International Investment)	Subsidiary
Topco Investment Co., Ltd. (Topco Investment)	Subsidiary
ECO Technology Services Co., Ltd. (Chien Yueh)	Subsidiary
Hong Kong Topco Trading Limited (Topco Trading)	Subsidiary
Kuan Yueh Technology Engineering Co., Ltd. (Kuan Yueh Technology)	Subsidiary
Jia Yi Energy Co., Ltd. (Jia Yi Energy)	Subsidiary
Kanbo Biomedical Co., Ltd. (Kanbo Biomedical)	Subsidiary (Note 2)
Jing Chen Energy Co., Ltd. (Jing Chen)	Subsidiary
Jing Yang Energy Co., Ltd. (Jing Yang)	Subsidiary
Anyong Biotechnology, Inc. (Anyong Biotechnology)	Subsidiary
Anyong FreshMart. Inc (Anyong Fresh Mart)	Subsidiary
Topchem Materials Co., Ltd. (Topchem Materials)	Subsidiary
Jing Yueh Energy Co., Ltd. (Jing Yueh Energy)	Subsidiary
Suzhou Topco Construction Ltd. (Topco Suzhou)	Subsidiary
Topco Scientific (Shanghai) Co. Ltd. (Topco Shanghai)	Subsidiary
Topco Chemical (Z.F.T.Z) Co., Ltd. (Topco Chemical)	Subsidiary
Topco Engineering (Suzhou) Ltd. (Topco Engineering)	Subsidiary
Topscience (s) Pte. Ltd. (Topscience (s))	Subsidiary
Yilan Anyong Lohas Co., Ltd. (Anyong Lohas)	Subsidiary
Xports Sports Co., Ltd. (Xports Sports)	Subsidiary
Unitech New Energy Engineering Co., Ltd (Unitech New Energy Engineering)	Subsidiary
Top Vacuum Co., Ltd. (Top Vacuum)	Subsidiary
Yun Yueh Technology Co., Ltd. (Yun Yueh Technology)	Subsidiary
Topchip electronic Co. Ltd. (Topchip)	Subsidiary
YAO YAE ENERGY CO., LTD. (YAO YAE ENERGY)	Subsidiary
Shunkawa Corporation (Shunkawa)	Subsidiary
Tai Ying Resource Industrial Corp. (Tai Ying Resource)	Subsidiary
Topco Scientific USA Corp. (Topco Scientific USA)	Subsidiary

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

<u>Name of related party</u>	<u>Relationship with the Company</u>
Top Energy Innovation Corporation LTD. (Top Energy Innovation)	Subsidiary
Topsience Vietnam Co., Ltd (Topsience Vietnam)	Subsidiary
Yong Yue Advanced Engineering Sdn Bhd. (Yong Yue Advanced Engineering)	Subsidiary (Note 1)
Ping Yue Technologies SDN. BHD. (Ping Yue Technologies)	Subsidiary
Carenity Health Management Co.,Ltd.(Carenity Health Management)	Subsidiary (Note 3)
Fong Rong Smart Machinery Co., Ltd. (Fong Rong Smart Machinery)	An associate of subsidiary
Eastwind Tsusho Inc. (Eastwind Tsusho)	An associate of subsidiary
Topco Quartz Products Co., Ltd. (Topco Quartz)	An associate of subsidiary
Shin-Etsu Handotai Taiwan Co, Ltd. (Shin-Etsu Handotai Taiwan)	The Company is the corporate director of the related party
Shin-Etsu Opto Electronics Co. Ltd. (Shin-Etsu Opto Electronics)	The Company is the corporate director of the related party
Topco Athletic Training Performance Development Association	Other related party
Maniflod Technology Co., Ltd. (Maniflod)	The Subsidiary is the corporate director of the related party

Note 1: The Company was established in August 2024.

Note 2: In May 2025, Kanbo Biomedical completed the distribution of assets and finished its liquidation.

Note 3: The Company was established in September 2025.

(b) Significant transactions with related parties

(i) Sales

1) Sales

The amounts of significant sales transactions between the Company and related parties were as follows:

	<u>2025</u>	<u>2024</u>
Subsidiaries	\$ 370,875	460,397
Associates	-	4,900
Other related parties	<u>13,198</u>	<u>12,554</u>
	<u>\$ 384,073</u>	<u>477,851</u>

Sales terms for related parties were similar to those of the third-party customers. The collection period was 30 to 90 days for both related parties and third party customers.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

2) Service revenue — commission and others

The amounts of significant service transactions between the Company and related parties were as follows:

	<u>2025</u>	<u>2024</u>
Subsidiaries	\$ 1,059	597
Associates:		
Topco Quartz	307,321	277,962
Other related parties:		
Shin-Etsu Handotai Taiwan	371,052	378,642
Other related parties	<u>1,200</u>	<u>320</u>
	<u>\$ 680,632</u>	<u>657,521</u>

The terms of transaction with related parties were based on the contracts signed between both parties, and there was no significant difference with the third-party customers.

(ii) Purchases

The amounts of significant purchase transactions between the Company and related parties were as follows:

	<u>2025</u>	<u>2024</u>
Subsidiaries	\$ 61,969	41,582
Associates	862,945	725,932
Other related parties	<u>51,277</u>	<u>21,915</u>
	<u>\$ 976,191</u>	<u>789,429</u>

Purchase terms for related parties were similar to those from third-party suppliers. The payment period was 30 to 90 days for both related parties and non-related parties.

(iii) Operating lease

The amounts of lease income recorded by the Company from leasing to related parties were as follows:

	<u>2025</u>	<u>2024</u>
Anyong Fresh Mart	\$ 2,207	1,016
Unitech New Energy Engineering	5,687	5,160
Chien Yueh	6,704	6,497
Other subsidiaries	<u>253</u>	<u>278</u>
	<u>\$ 14,851</u>	<u>12,951</u>

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

(iv) Other non-operating income

The Company entrusted Anyong Lohas to operate its tourism factory and Anyong Biotechnology to run its aqua-cultural product processing factory, respectively. Both of them share their operating results through revenue sharing agreements, based on which the Company was paid monthly.

	2025	2024
Subsidiaries	\$ 5,551	5,258

(v) Donation Expenses

The Group donated the both amount of \$35,000 to the other related parties of the Company, Topco Athletic Training Performance Development Association, and recognized is as operating expenses in statements of comprehensive income in 2025 and 2024.

(vi) Receivables from related parties

The receivables from related parties were as follows:

Account	Relationship	December 31, 2025	December 31, 2024
Accounts receivable	Subsidiaries	\$ 45,787	46,483
Accounts receivable	Associates	62,029	54,152
Accounts receivable	Other related parties	74,068	72,070
Other receivables	Subsidiaries	4,595	1,781
Other receivables	Associates	32	32
		\$ 186,511	174,518

(vii) Payables to related parties

The payables to related parties were as follows:

Account	Relationship	December 31, 2025	December 31, 2024
Accounts payable	Subsidiaries	\$ 17,386	5,797
Accounts payable	Associates	250,884	143,648
Accounts payable	Other related parties	6,734	11,970
		\$ 275,004	161,415

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

(viii) Guarantees

The credit lines of the guarantees the Company provided to related parties were as follows:

	<u>December 31,</u> <u>2025</u>	<u>December 31,</u> <u>2024</u>
Subsidiaries		
Topco Shanghai	\$ 100,400	184,607
Chien Yueh	2,045,000	2,045,000
Kuan Yueh Technology	1,196,984	1,136,984
TOPSCIENCE(s) Pte Ltd.	638,640	830,120
Other Subsidiaries	<u>3,446,282</u>	<u>2,372,787</u>
	<u>\$ 7,427,306</u>	<u>6,569,498</u>

(c) Transactions with key management personnel

Key management personnel compensation comprised:

	<u>2025</u>	<u>2024</u>
Short-term employee benefits	\$ 389,799	330,375
Post-employment benefits	<u>3,737</u>	<u>3,346</u>
	<u>\$ 393,536</u>	<u>333,721</u>

(8) Pledged assets:

The carrying values of pledged assets were as follows:

<u>Assets</u>	<u>Subject</u>	<u>December 31,</u> <u>2025</u>	<u>December 31,</u> <u>2024</u>
Other non-current financial assets	Deposit for lease		
– time deposits		\$ 2,380	1,880
Other current financial assets	Fees received in advance for sport training courses	8,817	5,163
Property, plant and equipment	Guarantees for long term borrowings	<u>5,323,911</u>	<u>5,334,597</u>
		<u>\$ 5,335,108</u>	<u>5,341,640</u>

(9) Commitments and contingencies:

(a) The Company's unrecognized contractual commitments were as follows:

	<u>December 31,</u> <u>2025</u>	<u>December 31,</u> <u>2024</u>
Commitments for construction contracts	\$ <u>87,989</u>	<u>169,263</u>
Bank guarantees to construction contracts	<u>\$ 20,677</u>	<u>39,256</u>

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

(b) The Company's unused and outstanding letters of credit for purchasing were as follows:

	December 31, 2025	December 31, 2024
Unused and outstanding letters of credit	\$ 1,214,191	1,073,594

(10) Losses Due to Major Disasters: None

(11) Subsequent Events: None

(12) Other:

(a) The followings are the summary statement of employee benefits, depreciation and amortization expenses by function:

By function By item	2025			2024		
	Operating cost	Operating expenses	Total	Operating cost	Operating expenses	Total
Employee benefit expenses						
Salaries	57,410	1,463,231	1,520,641	53,774	1,284,786	1,338,560
Labor and health insurance	2,600	66,884	69,484	2,429	61,735	64,164
Pension	959	34,198	35,157	899	32,451	33,350
Remuneration of directors	-	110,092	110,092	-	94,223	94,223
Other employee benefits	923	64,621	65,544	901	60,304	61,205
Depreciation	14,305	142,404	156,709	15,770	150,400	166,170
Amortization	65	12,706	12,771	299	15,076	15,375

The number of employees and employee benefit expenses of the Company for the years ended December 31, 2025 and 2024 were as follows:

	2025	2024
Number of employees	556	532
Non-employee directors	5	5
Average benefit expense per employee	\$ 3,069	2,841
Average salary expense per employee	\$ 2,760	2,540
Average salary expense adjustment per employee	8.66 %	

The Company's information of remuneration policy (including Board of Directors, managers and employees) was as follows:

(i) Employees:

Remuneration should be based on the Company's overall operating performance with consideration of the contribution of each Directors and executive officers to the Company and the risk the Company will face. The remuneration system is reviewed in a timely manner depending on the actual operating conditions and relevant laws and regulations to reach a balance between the Company's sustainable operation and risk control.

(Continued)

TOPCO SCIENTIFIC CO., LTD.
Notes to the Financial Statements

(ii) Managers:

The total compensation paid to the managers is decided based on their job responsibility, contribution and with reference to industry. The compensations are reviewed regularly in Remuneration Committee then submitted to the Board of directors for approval.

(iii) Directors:

The remunerations for the Directors are determined in accordance with the procedures set force in the Company's Article of Incorporation and the Company's overall operating performance. The compensations are reviewed regularly in Remuneration Committee then submitted to the Board of Directors for approval.

(13) Other disclosures:

- (a) Information on significant transactions: Please refer to table.
 - (i) Loans to other parties: Please refer to table 1
 - (ii) Guarantees and endorsements for other parties: Please refer to table 2
 - (iii) Securities held as of December 31, 2025 (excluding investment in subsidiaries, associates and joint ventures): Please refer to table 3
 - (iv) Related-party transactions for purchases and sales with amounts exceeding the lower of NT\$100 million or 20% of the capital stock: Please refer to table 4
 - (v) Receivables from related parties with amounts exceeding the lower of NT\$100 million or 20% of the capital stock: None
- (b) Information on investees: Please refer to table 5
- (c) Information on investment in mainland China: Please refer to table 6

(14) Segment information:

Please refer to the consolidated financial reports for the year ended December 31, 2025.

TOPCO SCIENTIFIC CO., LTD. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements

(i) Loans to other parties:

No.	Name of lender	Name of borrower	Account name	Related party	Highest balance of financing to other parties during the period	Ending balance	Actual usage amount during the period	Range of interest rates during the period	Purposes of fund financing for the borrower	Transaction amount for business between two parties	Reasons for short-term financing	Allowance for bad debt	Collateral		Individual funding loan limits (note 1)	Maximum limit of fund financing (note 1)
													Item	Value		
0	Topco Trading	Topsience Vietnam Co., Ltd	Other current financial assets related parties	Y	78,575	78,575	78,575	5.00%	Short term financing	-	Operating demand	-	NA	-	141,869	212,803

Note 1: Foreign currency amounts are translated to New Taiwan Dollars at the exchange rate at the end of the financial reporting date.

Note 2: According to the Company's "Operational Procedures for Lending of Capital to Others", the total amount of loans to a single enterprise shall not exceed 100%, respectively, of the net monetary amount of the financial reports of the latest month when transaction occurs, and the amount is \$141,869.

Note 3: According to the Company's "Operational Procedures for Lending of Capital to Others", the total amount of loans to others shall not exceed 150%, respectively, of the net monetary amount of the financial reports of the latest month when transaction occurs, and the amount is \$212,803.

(ii) Guarantees and endorsements for other parties:

(In Thousands of New Taiwan Dollars and foreign currencies)

No.	Name of guarantor	Counter-party of guarantee and endorsement		Limitation on amount of guarantees and endorsements for a specific enterprise	Highest balance for guarantees and endorsements during the period	Balance of guarantees and endorsements as of reporting date	Actual usage amount during the period	Property pledged for guarantees and endorsements (Amount)	Ratio of accumulated amounts of guarantees and endorsements to net worth of the latest financial statements	Maximum amount for guarantees and endorsements	Parent company endorsements/ guarantees to third parties on behalf of subsidiary	Subsidiary endorsements/ guarantees to third parties on behalf of parent company	Endorsements/ guarantees to third parties on behalf of companies in Mainland China
		Name	Relationship with the Company										
0	The Company	Topco Shanghai	(Note 2)	(Note 4)	307,215	100,400	100,400	-	0.50%	(Note 5)	Y	N	Y
"	"	Unitech New Energy Engineering	(Note 2)	(Note 4)	553,960	453,960	137,213	-	2.27%	(Note 5)	Y	N	N
"	"	Chien Yueh	(Note 2)	(Note 4)	2,045,000	2,045,000	254,208	-	10.23%	(Note 5)	Y	N	N
"	"	JiaYi Energy	(Note 2)	(Note 4)	387,132	207,132	70,132	-	1.04%	(Note 5)	Y	N	N
"	"	Jing Chen Energy	(Note 2)	(Note 4)	79,810	54,810	21,908	-	0.27%	(Note 5)	Y	N	N
"	"	Jing Yang Energy	(Note 2)	(Note 4)	128,830	128,830	109,890	-	0.64%	(Note 5)	Y	N	N
"	"	Jing Yueh Energy	(Note 2)	(Note 4)	159,834	159,834	142,825	-	0.80%	(Note 5)	Y	N	N
"	"	Kuan Yueh Technology	(Note 2)	(Note 4)	1,196,984	1,196,984	568,172	-	5.98%	(Note 5)	Y	N	N
"	"	Topsience(s)	(Note 2)	(Note 4)	852,395	638,640	341,490	-	3.19%	(Note 5)	Y	N	N
"	"	Topchem Materials	(Note 2)	(Note 4)	100,000	-	-	-	0.00%	(Note 5)	Y	N	N
"	"	Topsience Vietnam Co., Ltd.	(Note 2)	(Note 4)	722,890	722,890	92,760	-	3.61%	(Note 5)	Y	N	N
"	"	Topchip	(Note 2)	(Note 4)	565,631	505,591	351,087	-	2.53%	(Note 5)	Y	N	N
"	"	Topco Scientific USA	(Note 2)	(Note 4)	125,720	125,720	-	-	0.63%	(Note 5)	Y	N	N
"	"	YAO YUE ENERGY	(Note 2)	(Note 4)	59,800	59,800	3,983	-	0.30%	(Note 5)	Y	N	N
"	"	Yong Yue Advanced Engineering	(Note 2)	(Note 4)	293,540	157,150	-	-	0.79%	(Note 5)	Y	N	N
"	"	Ping Yue Technologies	(Note 2)	(Note 4)	36,693	31,430	-	-	0.16%	(Note 5)	Y	N	N
"	"	Xports Sports	(Note 2)	(Note 4)	80,000	80,000	35,000	-	0.40%	(Note 5)	Y	N	N
"	"	Top Energy	(Note 2)	(Note 4)	689,135	689,135	522,135	-	3.45%	(Note 5)	Y	N	N
"	"	Innovation Tai Ying Resource Grace&Partners.	(Note 2)	(Note 4)	70,000	70,000	40,000	-	0.35%	(Note 5)	Y	N	N
1	Chien Yueh	Architects and Planners	(Note 3)	(Note 6)	300,000	300,000	300,000	-	1.50%	(Note 6)	N	N	N
"	"	New Asia Construction & Development Corp.	(Note 3)	(Note 6)	7,544,000	7,544,000	7,544,000	-	37.72%	(Note 6)	N	N	N
2	Jia Yi Energy	Jing Yueh Energy	(Note 2)	(Note 7)	585	585	585	-	0.00%	(Note 7)	N	N	N
"	"	Kuan Yueh Technology	(Note 8)	(Note 7)	18,740	18,740	18,740	-	0.09%	(Note 7)	N	N	N
3	Xports Sports	Solomon Technology Corporation	(Note 9)	(Note 10)	48,000	48,000	48,000	-	0.24%	(Note 10)	N	N	N
4	Topco Suzhou	Topsience Vietnam Co., Ltd.	(Note 8)	(Note 4)	208,563	208,563	208,563	-	1.04%	(Note 11)	N	N	N
"	"	Shanghai Weijing Water Treatment Engineering	(Note 3)	(Note 4)	128,586	128,586	128,586	-	0.64%	(Note 11)	N	N	Y

Note 1: The Company is coded as "0", and its subsidiaries are coded consecutively in a numerical order starting from "1"

Note 2: Investee companies which have 50% of ordinary shares, directly or indirectly, owned by the Company.

Note 3: For the needs of the contracted work, the company is mutually insured by the contract between peers or co-founders.

Note 4: According to the Company's "Operational Procedures for Making Endorsements/Guarantees", the maximum amount of endorsements/guarantees for a single enterprise shall not exceed \$19,999,753, which is the net value of the Company's latest financial reports.

Note 5: According to the Company's "Operational Procedures for Making Endorsements/Guarantees", the maximum amount of endorsements/guarantees for others shall not exceed \$31,999,605, which is 160% of the net value of the Company's latest financial reports.

Note 6: According to the Chien Yueh "Operational Procedures for Making Endorsements/Guarantees", the maximum amount of endorsements/guarantees for a single enterprise shall not exceed \$16,519,140 and \$27,531,900, which is 30-50 times of the net value of the Chien Yueh's latest financial reports.

Note 7: According to the Jia Yi Energy's "Operational Procedures for Making Endorsements/Guarantees", the maximum amount of endorsements/guarantees for a single enterprise shall not exceed \$48,780 and \$97,561, which is 10-20 times of the net value of the Jia Yi Energy's latest financial reports.

Note 8: The company that directly or indirectly holds more than 90% of the company's voting shares.

Note 9: A company with which the corporation engages business.

Note 10: According to the Xports Sports "Operational Procedures for Making Endorsements/Guarantees", the maximum amount of endorsements/guarantees for a single enterprise shall not exceed \$152,371, which is 100% of the net value of the company's latest financial reports.

Note 11: According to the Topco Suzhou "Operational Procedures for Making Endorsements/Guarantees", the maximum amount of endorsements/guarantees for others shall not exceed \$21,898,400, which is 25% of the net value of the Company's latest financial reports.

Note 12: Due to the early renewal of the endorsement guarantee contract, the Company's endorsement guarantee to Chien Yueh, Kuan Yueh Technology, Unitech New Energy Engineering, Topchip, Topco Scientific USA and YAO YUE ENERGY was double-calculated in the amount NTD 700,000, NTD 300,000, NTD 50,000, USD 3,300, USD2,000 and NTD 29,900, respectively.

TOPCO SCIENTIFIC CO., LTD. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(iii) Material securities held as of December 31, 2024 (excluding investment in subsidiaries, associates and joint ventures):

(In Thousands of New Taiwan Dollars)

Name of holder	Category and name of security	Relationship with company	Account title	Ending balance				Note
				Shares/Units (thousands)	Carrying value	Percentage of ownship (%)	Fair value	
	Stock:							
The Company	Shin-Etsu Opto Electronic	The Company is its company director	Non-current financial assets at fair value through other comprehensive income	2,000	133,120	10	133,120	
"	Shin-Etsu Handotai Taiwan	"	"	12,000	1,280,400	8	1,280,400	
"	SOLAR APPLIED MATERIALS TECHNOLOGY CORP.	None	"	2,550	169,575	0.43	169,575	
"	Barits Biofund, Inc.	"	Non-current financial assets at fair value through profit or loss	7,216	144,318	3.52	144,318	
"	Shih Her Technologies Inc.	"	"	429	85,439	0.69	85,439	
"	Guangxin Venture Capital Co., Ltd.	"	"	10,000	118,900	6.67	118,900	
"	Belite Bio, Inc.	"	"	35	175,964	0.11	175,964	
"	Fu You Private Equity Fund Limited Partner	"	"	5,000	70,700	5.00	70,700	
"	Lin Bioscience, Inc.	"	"	485	192,536	0.59	192,536	
	Fund:							
Taiwan E&M	Mega Diamond Money Market Fund	None	Current financial assets at fair value through profit or loss	4,176	55,451	-	55,451	
"	UPAMC James Bond Money Market	"	"	2,850	50,330	-	50,330	
"	Taishin Ta-Chong Money Market Fund	"	"	3,330	50,108	-	50,108	

TOPCO SCIENTIFIC CO., LTD. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(iv) Related-party transactions for purchases and sales with amounts exceeding the lower of NT\$100 million or 20% of the capital stock:

Company Name	Counter party	Nature of relationship	Transaction details				Transactions with terms different from others		Notes/Accounts receivable (payable)		Note
			Purchase/(Sale)	Amount	Percentage of total purchases/(sales)	Payment terms	Unit price	Payment Terms	Ending Balance	Percentage of total notes/accounts receivable (payable)	
The Company	Topco Quartz	The Company's investment accounted for using equity method	Purchase	804,193	2.2%	Net 60 days from the end of the month of delivery	-	-	Accounts Payable (249,361)	(3.8%)	
"	Topco Shanghai	The Company's subsidiaries	Sale	(298,950)	(0.7%)	Net 60 days from the end of the month of delivery	-	-	Accounts receivable 44,714	0.7%	
Topco Shanghai	Shin Etsu Handotai Taiwan	The parent company of the company is its company director	Purchase	6,036,299	54.7%	Net 90 days from the end of the month of delivery	-	-	Accounts payable (1,384,754)	(65.4%)	
"	Wuxi Super Sunrise An Material	The Company's investment accounted for using equity method	Purchase	155,378	1.4%	Net 90 days from the end of the month of delivery	-	-	Accounts payable (24,957)	(1.2%)	
TOPCO SCIENTIFIC USA	Topco Quartz	The Company's investment accounted for using equity method	Purchase	412,662	28.0%	Net 60 days from the end of the month of delivery	-	-	Accounts payable (34,498)	(22.3%)	
TOPCO SCIENTIFIC USA	Shin Etsu Handotai Taiwan	The parent company of the company is its company director	Purchase	118,822	8.1%	Net 60 days from the end of the month of delivery	-	-	Accounts payable (11,958)	(7.7%)	
Topchip	Topco Shanghai	The Company's subsidiaries	Sale	(629,209)	(96.4%)	Net 15 days from the end of the month of delivery	-	-	Accounts receivable 35,336	99.5%	

TOPCO SCIENTIFIC CO., LTD. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements

(v) Information on investees:

The following is the information on investees for the year ended December 31, 2025 (excluding information on investees in Mainland China):

(In Thousands of New Taiwan Dollars and foreign currencies)

Investor Company	Investee Company	Location	Main Businesses and Products	Original Investment Amount		Balance as of December 31, 2025			Net income (losses) of investee	Share of profits/losses of investee	Note	
				46,022	45,657	Shares (thousands)	Percentage of Ownership	Carrying Value				
The Company	Topco Quartz	Hsinchu County	Manufacture and repair of quartz equipment, quartz tube e.g.	99,232	99,232	13	40.00%	2,628,216	1,268,272	502,374		
	Taiwan E&M	Hsinchu City	Sales of electronic material	425,000	425,000	42,500	100.00%	550,844	69,565	69,564		
	Fortune	Taipei City	Clean up of waste and environmental management service	149,600	149,600	14,960	24.93%	212,064	93,033	23,193		
	Topco Group	Samoa	Investment activities	714,206	714,206	22,432	100.00%	3,283,037	1,176,446	1,176,446		
	Topsience (s)	Singapore	Sales of parts of semiconductor and optoelectronic industries	411,513	411,513	6,577	100.00%	741,888	71,181	82,047		
	Topco International Investment	Taipei City	Investment activities	535,000	535,000	72,771	100.00%	790,298	96,939	96,939		
	Topco Investment	Taipei City	Investment activities	350,000	315,000	22,509	100.00%	104,650	(15,969)	(15,969)		
	Chien Yueh	Taipei City	Water purification and construction of dust-proof room	475,000	475,000	53,829	100.00%	488,957	121,421	94,536		
	Anyong Biotechnology	Kaohsiung City	Aquaculture and strategic partnership with fish processing	590,629	590,629	20,000	100.00%	89,918	(34,714)	(34,714)		
	Winfull Bio-tech Co., Ltd.	Tainan City	Manufacture of organic fertilizer	35,000	35,000	3,500	39.33%	-	-	-		
	Anyong Fresh Mart.	Taipei City	Wholesale and retail sales of fishery products and supermarket operation	749,350	749,350	24,500	100.00%	77,424	(44,394)	(44,371)		
	Jia Yi Energy	Taipei City	Manufacture of machinery and electronic spare parts	372,792	236,792	39,524	88.76%	358,446	28,440	19,835		
	Anyong Lohas	Yilan County	Restaurant and retail sales of food products	385,000	385,000	18,500	100.00%	13,762	(20,235)	(20,235)		
	Xsport Sports	Taipei City	Sports Training	240,508	180,508	24,500	100.00%	152,371	(40,584)	(40,584)		
	Unitech New Energy Engineering	Taipei City	Environment-related engineering planning, assessment, supervision and monitoring	434,560	434,560	776	77.60%	274,111	61,748	20,305		
	TOPCO SCIENTIFIC USA	USA	Wholesale of semiconductor material	152,011	152,011	10	100.00%	360,699	103,722	103,722		
	Topco Japan	Japan	Sales of facilities of semiconductor and clean room	86,714	86,714	50	100.00%	84,840	(3,233)	(3,233)		
	Yong Yue Advanced Engineering	Malaysia	Mechanical, electrical and water treatment engineering	20,987	20,987	2,860	100.00%	18,249	(2,882)	(2,882)		
									10,229,774		2,026,973	
	Topco Group	Topco Trading	Hong Kong	Wholesale of semiconductor material	47,145	47,145	1,500	100.00%	141,869	60,671	Investment gains (losses) recognized by Topco Group	
Asia Topco Holding		Cayman	Investment activities	(USD1,500)	(USD1,500)	20,000	100.00%	3,109,154	1,118,115	"		
Topco Korea		Korea	Diamond cutting, wafers, trading	628,600	628,600	100	100.00%	8,771	(2,334)	"		
Asia Topco Holding	Asia Topco	Mauritius	Investment activities	12,038	12,038	100	100.00%	8,771	(2,334)	"		
	Topscience Vietnam	Vietnam	Sales of parts of semiconductor and optoelectronic industries	(USD383)	(USD383)	20,000	100.00%	3,107,142	1,118,775	"		
Topscience (s)	Anyong (s)	Singapore	Wholesale and retail sales of fishery products	(USD20,000)	(USD20,000)	-	100.00%	77,727	10,000	Investment gains (losses) recognized by Topscience (s)		
	Ping Yue Technology	Malaysia	Sales of semiconductor material and equipment	108,754	108,754	3,146	100.00%	14,021	(1,096)	"		
	Topco International Investment	Taipei City	Wholesale sales of cosmetics	(SGD4,448)	(SGD4,448)	-	100.00%	77,727	10,000	Investment gains (losses) recognized by Topco International Investment		
Topco Investment	Kuan Yueh Technology	Taipei City	Development of renewable energy projects / Configure pipeline construction and device installation	9,780	9,780	400	100.00%	362	(1,024)	"		
	Jia Yi Energy	Taipei City	Manufacture of machinery and electronic spare parts	(SGD400)	(SGD400)	400	100.00%	362	(1,024)	"		
	Kanbo Biomedical	Taipei City	Sales of health food products	23,399	23,399	3,146	100.00%	14,021	(1,096)	"		
	Ruey Sheng Industrial Co., Ltd.	Samoa	Investment activities	(SGD957)	(SGD957)	3,146	100.00%	14,021	(1,096)	"		
	Topchem Materials	Taipei City	Antifouling surface protection, light-blocking material and the manufacture of other chemicals	37,000	37,000	6,100	100.00%	108,394	25,359	"		
	Fortune	Taipei City	Clean up of waste and environmental management service	771	771	40	0.07%	595	93,033	"		
	Tai Ying Resource	Kaohsiung City	Clean up of waste	178,261	178,261	14,392	65.42%	144,858	(9,307)	"		
	EastWind Tsusho	Taipei City	Manufacturing and trading of electronic parts, etc.	5,000	5,000	500	25.00%	6,610	3,328	"		
	Topchip	Taipei City	IC Design and Sales Company	50,000	50,000	5,000	100.00%	91,152	38,953	"		
	YAO YUE ENERGY	Taipei City	Sales of renewable energy	-	11,000	-	0.00%	-	4,743	"		
	Fong Rong Smart Machinery	Hsinchu City	Machinery manufacturing and repair industry	4,550	4,550	473	24.00%	5,711	(3,306)	"		
	Top Energy Innovation	Taipei City	Development of renewable energy project	-	9,000	-	0.00%	-	(1,396)	Investment gains (losses) recognized by Topco Investment		
	Fei Da Intelligent Co., Ltd.	Taipei City	Manpower dispatch	8,875	8,875	725	13.16%	(83)	(803)	"	Note 2	
STARX INC.	Hsinchu City	Precision instrument manufacturing	8,000	8,000	8,626	26.06%	4,681	(664)	"			
Yun Yueh Technology	Taichung City	Energy technology services	555	555	60	55.00%	522	4	"			
Great Talent Tech Co., Ltd.	Taipei City	Personnel training	5,000	5,000	250	17.85%	(3,322)	(2,105)	"			
Chongmu Health Co., Ltd.	Taipei City	Healthcare System Consulting Service Platform	4,800	4,800	800	33.33%	2,387	(2,039)	"			
Carenity Health Management Co., Ltd.	Taipei City	Healthcare System Consulting Service Platform	35,000	-	2,042	68.06%	34,642	(547)	"			

TOPCO SCIENTIFIC CO., LTD. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements

(In Thousands of New Taiwan Dollars and foreign currencies)

Investor Company	Investee Company	Location	Main Businesses and Products	Original Investment Amount		Balance as of December 31, 2025			Net income (losses) of investee	Share of profits/losses of investee	Note
				46,022	45,657	Shares (thousands)	Percentage of Ownership	Carrying Value			
Jia Yi energy	Jing Chen Energy	Taipei City	Development of renewable energy project	71,050	71,050	7,586	100.00%	74,092	(1,608)	Investment gains (losses) recognized by Jia Yi energy	
	Jing Yang Energy	Taipei City	"	86,497	86,497	8,795	100.00%	80,811	10,778	"	
	Jing Yueh Energy	Taipei City	"	92,160	92,160	9,624	100.00%	101,046	4,861	"	
	YAO YUE ENERGY	Taipei City	Sales of renewable energy	12,891	-	1,100	100.00%	15,829	4,743	"	
	Top Energy Innovation	Taipei City	Development of renewable energy project	139,755	-	14,500	100.00%	138,335	(1,396)	"	
Taiwan E&M	Top Vacuum	Hsinchu City	Vacuum pump equipment maintenance	45,035	45,035	6,000	60.00%	87,245	29,100	Investment gains (losses) recognized by Taiwan E&M	
	Equator Materials Corporation	Taichung City	Manufacture and sales of fine chemical materials	50,000	50,000	5,000	41.67%	33,194	(30,687)	"	
	Toplight Advanced Co., Ltd.	Hsinchu City	Laser cleaning factory and OEM business	20,000	20,000	2,000	66.67%	13,807	(7,731)	"	
Chien Yueh	Tai Ying Resource	Kaohsiung City	Clean up of waste	6,261	6,261	305	1.38%	3,158	(9,307)	Investment gains (losses) recognized by Chien Yueh	
	Unitech New Energy Engineering	Taipei City	Environment-related engineering planning, assessment, supervision and monitoring	5,600	5,600	10	1.00%	3,532	61,748	"	
	Reset Resource Technologies	Kaohsiung City	Clean up of waste	50,000	50,000	5,000	25.00%	42,039	(15,612)	"	
Topco Japan	Shunkawa	Japan	Import and export of semiconductor raw materials	60,240 (JPY300,000)	60,240 (JPY300,000)	30 -	100.00%	68,880 (JPY343,030)	2,246 (JPY10,778)	Investment gains (losses) recognized by Topco Japan	
Tai Ying Resource	Tai Ying Global Trading	Kaohsiung City	International Trading	15,000	15,000	1,500	100.00%	11,968	(728)	Investment gains (losses) recognized by Tai Ying Resource	

Note 1: The amounts in foreign currencies were translated into New Taiwan Dollars at the exchange rates at the ending date of the reporting period.

Note 2: The Group holds a seat of director of Fei Da Intelligent and has significant influence. As a result, the Group accounted it for using the equity method.

Note 3: The liquidation of assets was completed in September 2025.

TOPCO SCIENTIFIC CO., LTD. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements

(vi) Information on investment in Mainland China:

(i) The names of investees in Mainland China, the main businesses and products, and other information:

(In Thousands of US Dollars and CNY)

Name of investee	Main businesses and products	Total amount of paid in capital (Note 3)	Method of investment (Note 1)	Accumulated outflow of investment from Taiwan as of January 1, 2024 (Note 3)	Investment flows		Accumulated outflow of investment from Taiwan as of December 31, 2024 (Note 3)	Net income (losses) of the investee	Percentage of ownership	Investment gains (losses) (Note 2)	Book value (Note 3)	Accumulated remittance of earnings in current period
					Outflow	Inflow						
Topco Shanghai	Wholesale of electronic material and equipment	276,270 (USD 8,790) (Note 4)	Note 1	-	-	-	-	840,980 (USD 26,980)	100%	840,980 (USD 26,980)	1,890,703 (USD 60,156)	3,217,388 (USD 103,219)
Shanghai Chong Yao		58,448 (CNY 13,000)	Note 5	Note 5	-	-	-	27,838 (CNY 6,424)	100%	27,838 (CNY 6,424)	126,504 (CNY 28,137)	-
Topco Suzhou	Water purification and construction of dust-proof room	332,341 (USD 10,574) (Note 4)	Note 1	-	-	-	-	146,439 (USD 4,698)	100%	146,439 (USD 4,698)	875,923 (USD 27,869)	418,963 (USD 13,441)
Topco Chemical	Wholesale and sales of chemical products	22,504 (USD 716) (Note 4)	Note 1	-	-	-	-	130,262 (USD 4,179)	100%	130,262 (USD 4,179)	318,072 (USD 10,120)	649,344 (USD 20,832)
Topco Engineering	Water purification and construction of dust-proof room	89,919 (CNY 20,000)	Note 6	Note 6	-	-	-	4,533 (CNY 1,046)	100%	4,533 (CNY 1,046)	108,241 (CNY 24,075)	-
Shanghai Perfect Microelectronics	IC Design Company	8,992 (CNY 2,000)	Note 9	-	-	-	-	(364) (CNY (84))	49%	(178) (CNY (41))	4,487 (CNY 998)	-
Xinchongxin Technology	Used equipment refurbishment services	13,834 (CNY 3,077)	Note 12	-	-	-	-	(28,870) (CNY (6,662))	35%	(6,418) (CNY (1,481))	(1,250) (CNY (278))	-
Wuxi super sunrise material	Semiconductor wafer cassette recycling and cleaning service	134,879 (CNY 30,000)	Note 10	-	-	-	-	14,218 (CNY 3,281)	20%	4,403 (CNY 1,016)	45,166 (CNY 10,046)	-
Chongling Chemical	Wholesale and sales of chemical products	44,960 (CNY 10,000)	Note 11	-	-	-	-	156 (CNY 36)	0%	108 (CNY 25)	0	-

(ii) Limitation on investment in Mainland China:

Accumulated Investment in Mainland China as of December 31, 2024	Investment Amounts Authorized by Investment Commission, MOEA	Upper Limit on Investment
95,862 (USD 3,050) (Note 7)	727,039 (USD 23,132)	(Note 8)

Note 1 : Investment in Mainland China companies through an investee established in a third region.

Note 2 : The investment gains (losses) of Shanghai Perfect Microelectronics, Xinchongxin Technology, Wuxi super sunrise material and Chongling Chemical were recognized based on the financial statements which have been audited by the CPA; and the investment gains (losses) of other companies were recognized based on the financial statements prepared by the subsidiaries and not audited by the CPA.

Note 3 : The amounts in New Taiwan Dollars were translated at the exchange rate of USD 1:31.43 and CNY 1:4.496, respectively, as of December 31, 2025.

Note 4 : The paid-in capital of Topco Shanghai, Topco Suzhou and Topco Chemical includes the capital increase transferred from retained earnings amounting to USD1,990, USD7,874 and USD275, respectively.

Note 5 : Shanghai Chong Yao is jointly invested by Topco Shanghai and is Topco Suzhou, both of which are the subsidiaries of the Company.

Note 6 : Topco Engineering is invested by Topco Suzhou, which is the subsidiary of the Company.

Note 7 : Including the written-off investment funds of USD3,050.

Note 8 : The Company has acquired proof of compliance regarding the operational scope of the corporate headquarters issued by the Ministry of Economic Affairs. Therefore, there is no restriction to the Company's investing amount in Mainland China.

Note 9 : Shanghai Perfect Microelectronics was established by subsidiaries, Topco Shanghai and Shanghai Tx semiconductor, which held 49% and 51% of the capital contribution, respectively.

Note 10 : Wuxi super sunrise material was established by subsidiaries Topco Shanghai, Super natural technology, Wuxi Puli technology and Wuxi Xian Jeng which held 20%, 34%, 20% and 26% of the capital contribution, respectively.

Note 11 : Chongling Chemical was established by subsidiaries, Topco Chemical and Tianjin Linggas, Ltd. which held 70% and 30% of the capital contribution, respectively. Tax clearance procedures were completed in July 2025.

Note 12 : Xinchongxin Technology was established by subsidiaries Topco Shanghai, Qingfu Song and Jinping Zhang which held 35%, 55% and 10% of the capital contribution, respectively.

(iii) Significant transactions:

For year ended December 31, 2025, the significant inter-company transactions with the subsidiaries in Mainland China, which were eliminated in the preparation of consolidated financial statements, are disclosed in "Information on significant transactions".

Topco Scientific Co., Ltd.
Statement of Cash and Cash Equivalents
December 31, 2025
(Expressed in thousands of New Taiwan Dollars)

<u>Item</u>	<u>Description</u>	<u>Amount</u>
Cash on hand		\$ <u>2,255</u>
Checking accounts and demand deposits	NTD	608,504
	Foreign currencies (including USD 2,227 thousands, JPY 1,847,527 thousands, CNY 680 thousands and others)	<u>444,703</u>
		<u>1,053,207</u>
Time deposits	Foreign currency (including USD 9,500 thousands, maturity date: 2026.01.02~2026.01.07)	<u>298,585</u>
Total		<u>\$ 1,354,047</u>

Note: The exchange rate is 31.430 NTD for 1 USD ; 0.2008 NTD for 1 JPY and 4.496 NTD for 1 CNY.

Statement of Notes and Accounts Receivable

<u>Item</u>	<u>Description</u>	<u>Amount</u>
Notes receivable (Note)	Non-related party sales	\$ <u>2,087</u>
Accounts receivable :		
A Company	Non-related party sales	1,840,534
B Company	"	550,312
Others (Note)	"	<u>3,719,645</u>
		6,110,491
Less: Allowance for uncollectible accounts		<u>(10,112)</u>
Total		<u>\$ 6,102,466</u>

Note: The amount of individual customer included in others does not exceed 5% of the account balance.

Topco Scientific Co., Ltd.

Statement of Inventories

December 31, 2025

(Expressed in thousands of New Taiwan Dollars)

<u>Item</u>	<u>Cost</u>	<u>Net Realizable Value</u>
High technology products (Note 1)	\$ 2,728,433	3,086,966
Less : Allowance for loss on inventory	<u>(15,799)</u>	
	<u>2,712,634</u>	
Goods in transit	81,846	81,846
Others	<u>523</u>	<u>523</u>
Total	<u>\$ 2,795,003</u>	<u>3,169,335</u>

Note 1: Including integrated circuit, optoelectronics, packaging materials and electronic component products, etc.

Statement of other current assets, others

<u>Item</u>	<u>Description</u>	<u>Amount</u>
Prepayment for purchases	Prepaid accounts of vendors	\$ 141,400
Prepaid expenses	Prepaid rent and insurance, etc.	15,211
Temporary debits	Fees paid on behalf of employees and suppliers, etc.	48,870
Others (Note)	Prepaid stationery and postage, etc.	<u>1,966</u>
Total		<u>\$ 207,447</u>

Note : The amount of each item included in others does not exceed 5% of the account balance.

Topco Scientific Co., Ltd.

Statement of Changes in Investments Accounted for Using the Equity Method

For the year ended December 31, 2025

(Expressed in thousands of New Taiwan Dollars and Shares)

Investees Company	Balance, January 1, 2025		Increase (Decrease) (Note1)		Share of profits (losses) recognized	Amounts of exchanges difference on translation foreign operations	Other adjustment (Note2)		Balance, December 31, 2025			Market price or net value	Collaterals or pledged assets
	Shares	Amounts	Shares	Amounts			Shares	Amounts	Shares	Percentage of ownership	Amounts		
Topco Quartz	13	\$ 2,405,842		(280,000)	502,374	-	-	13	40 %	2,628,216	2,652,075	None	
Taiwan E&M	42,500	545,043		(63,910)	69,564	-	147	42,500	100 %	550,844	550,844	None	
Fortune	14,960	216,303		(27,432)	23,193	-	-	14,960	25 %	212,064	212,064	None	
Topco Group	22,432	3,494,131		(1,361,409)	1,176,446	(26,131)	-	22,432	100 %	3,283,037	3,265,641	None	
Topscience(s)	6,577	655,611		-	82,047	4,230	-	6,577	100 %	741,888	731,022	None	
Topco International Investment	72,771	742,487		(60,951)	96,939	-	11,823	72,771	100 %	790,298	864,804	None	
Topco Investment	19,009	89,197	3,500	35,000	(15,969)	-	(3,578)	22,509	100 %	104,650	104,650	None	
Chien Yueh	53,829	394,421		-	94,536	-	-	53,829	100 %	488,957	550,638	None	
Anyong Biotechnology	20,000	74,632		50,000	(34,714)	-	-	20,000	100 %	89,918	89,918	None	
Winfull Bio-tech Co., Ltd	3,500	-		-	-	-	-	3,500	39 %	-	-	None	
Anyong Fresh Mart	24,500	121,795		-	(44,371)	-	-	24,500	100 %	77,424	77,361	None	
Jia Yi Energy	25,924	202,252	13,600	135,951	19,835	-	408	39,524	89 %	358,446	432,973	None	
Anyong Lohas	18,500	33,997		-	(20,235)	-	-	18,500	100 %	13,762	13,762	None	
Xports Sports	18,500	132,955	6,000	60,000	(40,584)	-	-	24,500	100 %	152,371	152,371	None	
Unitech New Energy Engineering	776	326,227		(72,421)	20,305	-	-	776	77.6 %	274,111	65,066	None	
Topco Scientific USA	10	267,155		-	103,722	(10,178)	-	10	100 %	360,699	360,699	None	
Topco Japan	50	91,941		-	(3,233)	(3,868)	-	50	100 %	84,840	84,840	None	
Yong Yue Advanced Engineering	2,860	20,144		-	(2,882)	987	-	2,860	100 %	18,249	18,249	None	
Total		\$ 9,814,133		(1,585,172)	2,026,973	(34,960)	8,800			10,229,774			

Note1: The change in the current period included the cash dividend of \$1,866,172, the investment increase of \$281,000.

Note2: The Company increased its other equity by \$8,800 and capital surplus arising from the non-por rata subscription of new shares by \$0, based on its investee's adjustments by using International Financial Reporting Standards No. 9.

Topco Scientific Co., Ltd.
Statement of Changes in Property, Plant and Equipment
For the year ended December 31, 2025
(Expressed in thousands of New Taiwan Dollars)

Please refer to note 6(h).

Statement of Changes in Right-of-use Assets
For the year ended December 31, 2025

Please refer to note 6(i).

Statement of Long-term Borrowings
December 31, 2025

Please refer to note 6(l).

Topco Scientific Co., Ltd.
Statement of Notes and Accounts Payable
December 31, 2025
(Expressed in thousands of New Taiwan Dollars)

<u>Item</u>	<u>Description</u>	<u>Amount</u>
A Company	Non-related party operating costs	\$ 4,563,498
B Company	"	647,834
Others (Note)		<u>1,035,535</u>
Total		<u>\$ 6,246,867</u>

Note : The amount of individual vendor included in others does not exceed 5% of the account balance.

Statement of Other Current Financial Liabilities

<u>Item</u>	<u>Description</u>	<u>Amount</u>
Accrued payroll, bonuses, employees and directors' compensations	Estimated year-end bonuses, performance bonuses, employees benefits and employees and directors' compensations in 2025	\$ 992,121
Employees benefit liabilities	Provisions of employees' compensatory leave	41,199
Others (Note)	Accrued expense of vendors and employees and labor and health insurance expenses, etc.	<u>198,032</u>
Total		<u>\$ 1,231,352</u>

Note : The amount of each item included in others does not exceed 5% of the account balance.

Topco Scientific Co., Ltd.
Statement of Lease Liabilities
December 31, 2025
(Expressed in thousands of New Taiwan Dollars)

<u>Item</u>	<u>Lease term</u>	<u>Discount rate</u>	<u>Amount</u>
Land	5~8 years	1.56 %	\$ 6,330
Buildings	1~20 years	1.56 %	70,923
Vehicles	3~4 years	1.56 %	<u>29,505</u>
			106,758
Less: classified as current portion			<u>(39,698)</u>
Non-current lease liabilities			<u><u>\$ 67,060</u></u>

Statement of Operating Revenues
For the year ended December 31, 2025

<u>Item</u>	<u>Quantity</u>	<u>Amount</u>
Semiconductor and optoelectronics related products	Note	\$ 40,728,336
Others		<u>85,451</u>
		<u><u>\$ 40,813,787</u></u>

Note: Due to the many of different kinds of product unit and no consistent methodology of unit quantification; therefore, the quantity was not disclosed.

Topco Scientific Co., Ltd.
Statement of Operating Costs
For the year ended December 31, 2025
(Expressed in thousands of New Taiwan Dollars)

<u>Item</u>	<u>Amount</u>
Inventories, beginning of the year	\$ 2,251,982
Add: Purchase of inventories	36,235,863
Less: Inventories, end of the year	(2,810,802)
Transferred to operating expenses and others	(34,155)
Transferred to other operating costs-maintenance costs and construction in progress	<u>(19,235)</u>
Cost of sales	35,623,653
Indemnity of inventories and others	9,111
Reversal of allowance for loss on inventories	<u>9,850</u>
	<u>35,642,614</u>
Other operating costs	<u>273,929</u>
Operating costs	<u><u>\$ 35,916,543</u></u>

Statement of Operating Expenses

<u>Item</u>	<u>Selling expenses</u>	<u>Administrative expenses</u>	<u>Research and development expenses</u>	<u>Total</u>
Wages and salaries	\$ 460,138	987,679	15,414	1,463,231
Depreciation	36,567	104,003	1,834	142,404
Shipping expenses	64,359	822	80	65,261
Others (Note)	<u>267,874</u>	<u>500,097</u>	<u>8,996</u>	<u>776,967</u>
Total	<u><u>\$ 828,938</u></u>	<u><u>1,592,601</u></u>	<u><u>26,324</u></u>	<u><u>2,447,863</u></u>

Note : The amount of each item included in others does not exceed 5% of the account balance.